Abstract Supplement

HIV & Hepatitis in the Americas
28–30 April 2016, Mexico City, Mexico

NEW DRUGS FOR HEPATITIS

REFLECTIONS ON START

HEPATITIS C IN LATIN AMERICA

ART MANAGEMENT

PERSPECTIVES IN HIV

PREP AND IMPLEMENTATION

BARRIERS TO ACCESS

MOTHER-TO-CHILD TRANSMISSION

HIV CURE - HIV/HEPATITIS AND DRUG USE

COST-EFFECTIVENESS

KEYNOTE LECTURES

NEW STRATEGIES/TARGETS

POLICY MEETS PRACTICE

AGEING AND HIV

PERSPECTIVES IN HIV

PUBLIC HEALTH

NEW DRUGS FOR HEPATITIS

PREP AND IMPLEMENTATION

BARRIERS TO ACCESS

MOTHER-TO-CHILD TRANSMISSION

HIV CURE - HIV/HEPATITIS AND DRUG USE

COST-EFFECTIVENESS

KEYNOTE LECTURES

NEW STRATEGIES/TARGETS

POLICY MEETS PRACTICE

AGEING AND HIV

PERSPECTIVES IN HIV

PUBLIC HEALTH
The development of potent interferon-free regimens of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection has moved at a remarkable pace. Highly effective, extremely well-tolerated regimens are now available for most patient populations. Remarkably, advances have moved as quickly for those with HIV–HCV co-infection as for those with HCV monoinfection, with recent studies showing similar results with most regimens in both populations. This has raised the question of whether HIV co-infection continues to represent a “special” population among HCV-infected individuals. There are, however, some data suggesting that HIV may still impair responses in particularly difficult-to-cure populations. For example, attempts to shorten therapy to eight weeks with sofosbuvir/NASSA combinations have been at least somewhat less successful in HIV-co-infected patients than in those with HCV monoinfection. It is clear that innate and possibly adaptive immune function are still necessary for viral clearance even with highly effective DAA-based regimens, and thus, it is possible that particularly as therapy is pushed to shorter and simpler combinations, HIV may again emerge as an issue necessitating special consideration. The rationale behind DAA combinations will be reviewed with a focus on relevance for HIV–HCV co-infection. A general discussion of remaining issues to be addressed including drug interactions and treatment access will also be included.

http://dx.doi.org/10.7448/IAS.19.2.21010

**KL11**

**What about the new drugs for hepatitis?**

**Jordan Feld**

Toronto Western Hospital Liver Center, Toronto, ON, Canada

The advent of potent combination antiretroviral therapy (ART) has led to a dramatic decrease in the incidence of AIDS and AIDS-related mortality worldwide. For most patients, full suppression of HIV type 1 (HIV-1) replication can be achieved by once-daily administration of an ART regimen available as a fixed-dose combination that is safe, convenient and well tolerated. Nevertheless, a treatment that led to durable drug-free remission or eradication (cure) of HIV-1 could reduce the burden, cost, toxicities and stigma associated with long-term ART and might lower immune activation and the associated risk of non-AIDS clinical events. The search for a cure therefore remains a high priority for clinicians, investigators and patients. To date, only a single individual (a Mr Timothy Ray Brown, known as the “Berlin” patient) has had apparent cure of HIV infection. In his case, the patient underwent allogeneic hematopoietic stem cell transplantation for treatment of acute myelogenous leukaemia using cells from a donor homozygous for a deletion in the CCR5 gene. Although ART was stopped at the time of transplantation, HIV did not rebound and has remained undetectable during more than seven years of follow-up. Attempts to repeat this approach in other patients have been unsuccessful to date. Current efforts at eradicating HIV infection or inducing long-term ART-free remission include activating HIV transcription in latently infected CD4+ T-cells, enhancing HIV-specific immunity in order to target and destroy cells harbouring latent infectious proviruses and employing cell-based therapies using genetically modified CD4+ T-cells or hematopoietic stem cells. Several exploratory pilot studies are underway with each of these approaches. Major challenges include the difficulty of quantifying the HIV reservoir, the uncertain safety of the experimental treatments under study and the need to balance the risk of these interventions against the generally well-tolerated and proven efficacy of long-term ART. Recent progress towards a cure presented at the 2016 CROI in Boston will be discussed.

http://dx.doi.org/10.7448/IAS.19.2.21011

**KL12**

**Injection drug use and HIV/HCV epidemics**

**Nora D Volkow**

National Institute on Drug Abuse (NIDA), Bethesda, MA, USA

Injection drug use (IDU) is an important vector in HIV and hepatitis C virus (HCV) transmission. Though the United States, Canada and western Europe have had major successes in controlling the HIV epidemic due to IDU, that is not the case in eastern Europe and Southeast Asia. Moreover, the recent increases of IDU in the United States fuelled by the epidemic of prescription opioid abuse were responsible for last year’s HIV outbreak in Indiana and for the increases in HCV across the country and highlight the continued importance of IDU in fuelling these two epidemics. Injecting drug users infected with HIV or HCV can quickly lead to generalized HIV and HCV epidemics as they serve as bridges to other populations through sexual transmission. This highlights the importance of addiction treatment of IDU (particularly medication-assisted treatment or MAT) as prevention strategy for HIV and HCV infection as well as “antiretroviral therapy treatment as prevention strategy” to prevent HIV transmission. Addiction treatment also improves adherence to antiretroviral and clinical outcomes for HIV. The role of MAT in the prevention and outcomes for HCV has been much less studied. However, despite the effectiveness of MAT for the treatment of opioid use disorders, its use in IDU is very restricted. Strategies are required to expand its use within the healthcare system including infectious disease clinics as well as criminal justice settings. Success in its implementation will be necessary for achieving an AIDS-free generation and also for containing the growing HCV epidemic.

http://dx.doi.org/10.7448/IAS.19.2.21009

**KL31**

**HIV cure research: update from CROI 2016**

**Daniel R Kuritzkes**

Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

The advent of potent combination antiretroviral therapy (ART) has led to a dramatic decrease in the incidence of AIDS and AIDS-related mortality worldwide. For most patients, full suppression of HIV type 1 (HIV-1) replication can be achieved by once-daily administration of an ART regimen available as a fixed-dose combination that is safe, convenient and well tolerated. Nevertheless, a treatment that led to durable drug-free remission or eradication (cure) of HIV-1 could reduce the burden, cost, toxicities and stigma associated with long-term ART and might lower immune activation and the associated risk of non-AIDS clinical events. The search for a cure therefore remains a high priority for clinicians, investigators and patients. To date, only a single individual (a Mr Timothy Ray Brown, known as the “Berlin” patient) has had apparent cure of HIV infection. In his case, the patient underwent allogeneic hematopoietic stem cell transplantation for treatment of acute myelogenous leukaemia using cells from a donor homozygous for a deletion in the CCR5 gene. Although ART was stopped at the time of transplantation, HIV did not rebound and has remained undetectable during more than seven years of follow-up. Attempts to repeat this approach in other patients have been unsuccessful to date. Current efforts at eradicating HIV infection or inducing long-term ART-free remission include activating HIV transcription in latently infected CD4+ T-cells, enhancing HIV-specific immunity in order to target and destroy cells harbouring latent infectious proviruses and employing cell-based therapies using genetically modified CD4+ T-cells or hematopoietic stem cells. Several exploratory pilot studies are underway with each of these approaches. Major challenges include the difficulty of quantifying the HIV reservoir, the uncertain safety of the experimental treatments under study and the need to balance the risk of these interventions against the generally well-tolerated and proven efficacy of long-term ART. Recent progress towards a cure presented at the 2016 CROI in Boston will be discussed.

http://dx.doi.org/10.7448/IAS.19.2.21011

**KL32**

**Hepatitis C eradication: is it possible?**

**Michael Saag**

Division of Infectious Disease, University of Alabama at Birmingham, Birmingham, AL, USA

Over the last five years, the release of multiple direct acting antiviral (DAA) agents has created a therapeutic revolution in the world of hepatitis C (HCV) treatment. These novel, short-course (12 weeks) all-oral regimens can routinely cure HCV infection in the vast majority of patients, regardless of genotype or liver fibrosis stage, in essence replacing completely the use of injectable peginterferon and its attendant side effects. Based on these striking developments, a clear message is emerging that virtually every patient with chronic HCV should be treated . . . Now! If such a policy is enacted, we can eradicate HCV within a decade or two, resulting in a marked reduction in disease burden and eliminating all new infections. Whether we achieve this aspirational goal depends on our collective will and creative solutions to access clinics prepared to treat HCV and solutions to access medicines, most of which are priced beyond the...
reach of many health systems. Several emerging concepts suggest we can begin to achieve our goal of eradication and the barriers can be overcome. The solutions are embedded in standard approaches of public health epidemiology, health policy, provider education and creative negotiations. Eradication is possible. It is up to us to make it so.

http://dx.doi.org/10.7448/IAS.19.2.21012

KL33

Where is the HIV pipeline going (and does it matter)?
Roy Gulick
Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA

There are 29 antiretroviral drugs and five one-pill, once-daily oral formulations approved for the treatment of HIV infection. Despite their demonstrated benefits, some antiretroviral regimens may be inconvenient, toxic and/or have suboptimal virologic activity, particularly against drug-resistant strains. Thus, newer compounds and formulations are needed that continue to improve convenience and tolerability, reduce side effects and toxicity, and improve antiretroviral activity against drug-resistant viruses. There are a number of investigational antiretroviral agents currently in development, both in existing classes and new mechanistic classes. Tenofovir alafenamide is a new pro-drug of tenofovir that completed phase 3 testing and demonstrates potent virologic activity and reduced renal and bone toxicity. Doravirine is an investigational NNRTI currently in phase 3 clinical trials that has potential for fewer drug–drug interactions and activity against NNRTI-resistant viruses. Cabotegravir is an investigational integrase inhibitor in phase 3 clinical trials that can be given in a parenteral form with a long half-life supporting every 2 to 3 month dosing. Newer antiretroviral agents may exploit viral or cellular targets with new mechanisms of action. These include the investigational oral small-molecule CD4 attachment inhibitor, BMS-663068, that currently is in phase 3 clinical trials, and the investigational oral HIV maturation inhibitor, BMS-955176, that currently is in phase 2b clinical trials. Additional investigational agents, both in existing and newer antiretroviral mechanistic classes, and newer drug formulations of existing drugs are in development. Continued progress in HIV drug development will help improve the clinical care of patients living with HIV infection.

http://dx.doi.org/10.7448/IAS.19.2.21013
O12 - PrEP: THE TIME HAS COME

O121
PreP and implementation: a work in progress
Kenneth Mayer
The Fenway Institute, Fenway Health, Boston, MA, USA

Multiple randomized, controlled trials of oral tenofovir disoproxil fumarate with or without co-formulated emtricitabine (TDF/FTC) used for pre-exposure prophylaxis (PrEP) in high-risk people have demonstrated high levels of protective efficacy among those who were adherent. PrEP has been found to be protective in men who have sex with men (MSM), young heterosexuals, transgender women and injection drug users, although suboptimal medication adherence in some studies of young African women led to inconclusive results. TDF/FTC has been generally safe and well tolerated, though the potential for nephrotoxicity requires ongoing clinical monitoring. Statistically significant, reversible changes in bone mineral density have been observed, though the findings have not been associated with clinical disease. Concerns have been raised regarding the potential for behavioural disinhibition, but the reality is that most PrEP users have had long-standing low levels of condom use, so it is more accurate to conclude that PrEP is associated with ongoing risk maintenance. Highly adherent PrEP users are at increased risk for other sexually transmitted diseases (STDs) if condoms are not routinely used, so quarterly STD screening is warranted. Pharmacological studies and post hoc analyses of recent trials suggest that for men who have sex with men, there may be a level of pharmacological forgiveness, because of high concentrations of tenofovir and FTC in rectal mucosa, so that less than daily dosing can be highly effective. One study found that MSM who took two TDF/FTC doses within 24 h of condomless intercourse and a pill a day for two days after achieved 86% protection. However, because of relatively lower concentrations in cervicovaginal mucosa, it is advisable that women be highly adherent to a daily TDF/FTC PrEP regimen. Other approaches to antiretroviral chemoprophylaxis are under study. Studies of antiretroviral-containing vaginal rings and injectable PrEP are underway. Regulatory bodies concerned about the robustness of the approach in the setting of suboptimal adherence, potential behavioural disinhibition, selection for drug resistance and the costs of prophylaxis in constrained economic settings. However, evidence from demonstration projects in multiple settings, including projects in Brazil, Australia, South Africa, Kenya and the United States, suggest that individuals who self-select to use PrEP are usually adherent and that the regimen is protective and well tolerated. PrEP will continue to evolve, but its importance as another tool to arrest HIV transmission continues to grow.

http://dx.doi.org/10.7448/IAS.19.2.21014

O21 - THE CHALLENGE OF BRINGING RESEARCH TO POLICY AND INTO CLINICAL PRACTICE

O211
HAART for advanced patients. Why, what and how?
Omar Sued
Clinical Research, Fundación Huesped, Buenos Aires, Argentina

Late presenters represent a significant proportion of HIV-diagnosed patients. The factors that contribute to their late diagnosis might also contribute to poor adherence after initiating treatment, including lack of social support, active drug use or lack of knowledge about HIV and the benefits of highly active antiretroviral therapy. HIV diagnosed at advanced stage is associated with several adverse outcomes including clinical progression, blunted immune recovery after treatment, greater risk of drug toxicity and increased risk of immune reconstitution inflammatory syndrome. Randomized studies in patients presenting with opportunistic infections, including trials involving patients with pulmonary TB, have demonstrated the benefit of initiating treatment early, although controversy remains regarding the optimal time for initiating ART in patients with meningal TB or meningal cryptococosis. A significant proportion of advanced patients will require intensive care. Maintaining or initiating ART during an intensive care unit admission presents distinct challenges related to drug distribution, drug doses, drug interactions and antiretroviral-associated toxic effects. Finally, randomized trials have evaluated the efficacy of different NNRTI and PI combinations in advanced patients, while studies exploring other combinations are underway.

http://dx.doi.org/10.7448/IAS.19.2.21015

O212
Comprehensive care for elderly HIV-positive patients
Nestor Sosa
The Gorgas Memorial Institute for Health Studies, Panama City, Panama

With the success of antiretroviral therapy, more patients with HIV are living longer, and thus, a greater proportion of people living with HIV are older than 50 years of age. Besides, new HIV infections continue to occur among older adults, and late presentation, delayed diagnosis and rapid progression to AIDS have been reported in this age group. Healthcare providers should concentrate not only on screening for HIV, preventing the progression to AIDS and treating opportunistic infections, but also on the comprehensive management of this ageing patient population. There is evidence that older HIV-positive subjects have more comorbidity, are frequently treated with polypharmacy and are disproportionately affected by neurocognitive impairment. Conditions like osteoporosis, diabetes, cardiovascular disease, cancer, chronic renal disease and hyperlipidaemia are common among older adults living with HIV. Selection of antiretroviral therapy, attention to drug–drug interactions, anticipating and preventing the exacerbation of pre-existing comorbid conditions are issues that required special attention in the care of elderly HIV-positive individuals. We will review the evidence supporting some of the recommendations on how to treat older adults with HIV infection, and we will remark some of the peculiarities of the HIV infection in the elderly.

http://dx.doi.org/10.7448/IAS.19.2.21016

O213
Best practices for monitoring of HIV virologically suppressed patients
Ricardo Sobhie Diaz
Infectious Diseases Division, Paulista School of Medicine, Federal University of São Paulo and Retrovirology Laboratory, São Paulo, Brazil
As the efficacy of antiretroviral treatment is maximized over time with the use of more potent, convenient and better tolerated drugs, and as a consequence of the test and treat era, there will be a growing number of virologically suppressed HIV-positive individuals over time. A number of virologically suppressed patients have been also under antiretroviral treatment for long periods, and individuals are growing older with emerging age-related comorbidities and polypharmacy. Monitoring laboratory tests for HIV antiretroviral treatment have been evaluated for this new era to come, and new questions naturally emerge. How frequently should HIV viral loads monitoring be performed for long-term suppressed patients? How to manage low-level viremia among these individuals, and what is the real significance for low-level viremia among those patients? Is CD4+ T-cell counts monitoring necessary among virologically suppressed individuals? Are genotyping or tropism tests on peripheral blood mononuclear cells of use as tool for antiretrovirals switch or antiretroviral de-intensification? Are cell activation markers promising to design strategies in order to mitigate chronic HIV-related inflammation? Blood tests for safety should also be carefully strategized in the future. Toxicities may emerge due to long-term use of antiretrovirals, age-related frailties and organ/tissues degeneration, and antiretroviral interactions with polypharmacy. It is also conceivable that long-term antiretroviral suppression may facilitate cancer emergency, specially lymphoma, due to the clonal expansion of lymphocytes with HIV integration in cancer genes [1,2].

References
1. Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, et al. HIV latency: Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science. 2014;345(6193):179–83.
2. Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, et al. HIV latency: Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science. 2014;345(6196):570–3.

http://dx.doi.org/10.7448/IAS.19.2.21017

O22 - AGEING AND CAUSES OF DEATH IN HIV+ PATIENTS, AND ORAL PAPERS

O221

Ageing and HIV: from bench to clinic
Peter Hunt
HIV/AIDS Division, University of California San Francisco, San Francisco, CA, USA

While HIV-positive individuals with access to modern antiretroviral therapy (ART) have experienced a dramatic improvement in life expectancy, they remain at higher risk than the general population for morbidity and mortality, particularly from non-AIDS complications typically associated with ageing. While lifestyle factors (e.g., smoking, illicit drug use and obesity) as well as ART toxicities likely play a role, it is now well recognized that abnormal immune activation and inflammation persist in many ART-suppressed individuals, including those that restore normal CD4+ T-cell counts, and that the extent of these immunologic defects strongly predicts morbidity and mortality from non-AIDS conditions. Interestingly, while some of the immunologic predictors of morbidity and mortality overlap with those of ageing, many are unique to HIV infection, suggesting distinct interventional targets. Multiple causes of the persistent inflammatory state in treated HIV infection have been proposed including HIV persistence, microbial translocation, cytokemavirus and other prevalent co-infections. While earlier initiation of ART appears to be beneficial in reducing the inflammatory state and in reducing some morbidities, and some commonly used medications with anti-inflammatory properties (e.g., statins) have shown some promise in pilot studies, there is a clear need for effective interventions to reverse persistent immune activation in this setting. These issues will become increasingly important as the HIV epidemic gets older, particularly in resource-limited settings, where the vast majority of HIV-positive individuals live.

http://dx.doi.org/10.7448/IAS.19.2.21018

O222

What the HIV-positive patients dying from? Data from across the region
Paco F Belaunzarán Zamudio
National Institute of Medical Sciences and Nutrition, Mexico City, Mexico

The expansion of universal access programmes worldwide has dramatically reduced morbidity and mortality, albeit in a different manner regionally. While the HIV epidemic in high-income countries has gone through a clear epidemiologic transition in which cardiovascular, non-AIDS neoplasias and chronic non-transmissible diseases have become the predominant cause of death among people living with HIV, limited data from Latin America and the Caribbean region suggest a more modest and apparently earlier phase of the transition in which most people with HIV still die of potentially preventable opportunistic infections early after diagnosis. Non-AIDS associated causes of death are increasing heterogeneously throughout the region but are not yet predominant. The information available about causes of death among people living with HIV at the national level in most countries in Latin America and the Caribbean is scarce. National and regional data for Brazil, and regional or single-centre published information for several countries in Latin America suggest that the impact of the expansion of universal access to antiretroviral therapies on mortality has been heterogeneous across the region and has decreased mortality the least among women. Evidence from Brazil shows that chronic non-communicable diseases have steadily increased as a cause of death in the last decade but tuberculosis and endemic transmissible diseases (e.g. histoplasmosis and visceral leishmaniasis) continue to kill a very high proportion of people living with HIV. Evidence from other countries appears to confirm this pattern happening at different rates regionally. The high prevalence of late diagnosis, shortcomings of health systems, maturity of expanded access programmes and ageing of the epidemic are most likely shaping this transition.

http://dx.doi.org/10.7448/IAS.19.2.21019

O223

Viral load and CD4 + T-cell count dynamics in a large cohort of individuals with primary HIV-1 infection in Brazil
Patricia Lima Hottz1; Antonio Guilherme Fonseca Pacheco2; Karine Milani da Silva3; Natalia Cerqueira3; Mariana Mellilo Sauer3; Esper Georges Kallas1 and Mauro Schechter5
1Hospital Universitário Clementino Fraga Filho/Universidade Federal do Rio de Janeiro, Infectious Diseases, Rio de Janeiro, Brazil. 2Fundação Oswaldo Cruz (Fiocruz), PROCC, Rio de Janeiro, Brazil. 3School of Medicine/University of Sao Paulo, Division of Clinical Immunology and Allergy, Sao Paulo, Brazil. 4Projeto Praca Onze/Hospital Escola Sao Francisco de Assis/Universidade Federal do Rio de Janeiro, Infectious Diseases, Rio de Janeiro, Brazil.
**Introduction:** There is limited information about the natural history of HIV-1 infection in Latin American countries [1]. This study describes the trajectories of the plasma viral load and CD4+ T-cell (CD4) counts in individuals with documented primary HIV-1 infection in Rio de Janeiro and Sao Paulo, between 1989 and 2013. This is the largest study ever conducted in Brazil and one of the few in Latin America that have investigated the natural trajectories of these important predictors of HIV-1 disease progression.

**Methods:** This retrospective cohort study analyzed viral load and HIV-RNA CD4 counts of 307 individuals with documented primary or recent HIV-1 infection (within 12 months) in Rio de Janeiro and Sao Paulo. Follow-up was censored at the last visit or at the start of antiretroviral therapy. The impact of demographic and clinical variables such as gender, age at seroconversion, race, occurrence of symptoms compatible with the acute retroviral syndrome on the dynamics of viral load and CD4 counts was analyzed. Generalized additive mixed effects models with Poisson response were used in the modelling of CD4 counts and viral load measures. The time between seroconversion and CD4 decline to less than 350 cells/mm3 was analyzed by Kaplan-Meier survival curves. The Cox model was used to estimate the effects of the various strata.

**Results:** The median initial CD4 counts and viral loads were 512.5 (range 390.8 to 684.2) cells/mm3 and 4.31 (range 3.61 to 4.85) log_{10} cps/mL, respectively. The median time of CD4 decline to <350 cells/mm3 was 588 (interquartile range: 458 to 864) days. Non-white individuals were at an increased risk of a faster decline of CD4 counts (Figure 1). Older age was a risk factor for lower CD4 counts at seroconversion and to faster declines to CD4 counts. Due to the current recommendations for treatment of HIV-1 infection regardless of CD4+ T-cell count, it is unlikely that similar studies will be conducted in the future, which increases its importance, particularly for the discussion of the cost-effectiveness of various possible prioritization strategies for testing and initiation of antiretroviral therapy.

**Conclusion:** Due to the current recommendations for treatment of HIV-1 infection regardless of CD4+ T-cell count, it is unlikely that similar studies will be conducted in the future, which increases its importance, particularly for the discussion of the cost-effectiveness of various possible prioritization strategies for testing and initiation of antiretroviral therapy.

**Reference:**
1. Djomand G, Duerr A, Faulhaber JC, Struchiner CJ, Pacheco AG, Barroso PF, et al. Viral load and CD4 count dynamics after HIV-1 seroconversion in homosexual and bisexual men in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr. 2006;43(4):401–4.

http://dx.doi.org/10.7448/IAS.19.2.21020

**O224**
**ART initiation rates and first-line regimens in Latin America remain a challenge for WHO recommendations**

Isabel Cassetti1; Pablo Parenti2; William Lenis3; Rosa Teran4; Alberto Castillo5; Ana Belen Arauz6 and Miguel Morales7

1Latin American HIV Workshop Study Group, AIDS, Buenos Aires, Argentina. 2Latin American HIV Workshop Study Group, AIDS, Rosario, Argentina. 3Latin American HIV Workshop Study Group, AIDS, Cali, Colombia. 4Latin American HIV Workshop Study Group, AIDS, Quito, Ecuador. 5Latin American HIV Workshop Study Group, AIDS, Panama City, Panama. 6Latin American HIV Workshop Study Group, AIDS, Caracas, Venezuela

**Introduction:** WHO Consolidated Guidelines released in November 2015 recommend antiretroviral therapy (ART) initiation in all adults living with HIV regardless of clinical stage and at any CD4 count. The preferred first-line regimen is TDF + 3TC (FTC) + EFV with NVP, EFV 400 mg and DTG as alternative regimens as well as AZT + 3TC in place of TDF + 3TC. Latin American countries follow local specific guidelines, each one recommending different approaches for time and ART combinations for ART initiation. The aim of this study is to determine how often ART is initiated in new HIV cases and what antiretroviral combinations are used in clinical practice in countries from Latin America.

**Materials and methods:** The Latin American Workshop Study Group is an expanding network of 38 HIV Care Centers from 11 countries of South America, Central America, the Caribbean and Mexico with clinical data from 73,431 patients up to September 2015. We identified 9879 cases of ART initiation in 2013 to 2014 in eight countries. Statistical analysis by chi-square test and confidence intervals.

**Results:** Globally, 81% of newly diagnosed HIV cases initiated ART during the first year of follow-up. Mexico, Dominican Republic and Argentina were the only countries with rates of ART initiation of 90% or higher, while rates of ART initiation were 64% to 74% in most South American countries. Only 16% of patients initiated TDF + 3TC/FTC + EFV. AZT + 3TC is still the preferred backbone (52.2%), while TDF + 3TC/FTC is the second preferred backbone (24.1%) with large differences in NRTI use between countries: less than 25% in Costa Rica and Peru but over 90% in Ecuador and Mexico. EFV is the third drug in 65.4% of therapies initiated in 2013 to 2014, protease inhibitors in 18.3% of cases and Raltegravir in 2.4%.

**Conclusions:** In Latin America, some countries adopted ART initiation regardless of CD4 count, while most South American countries show ART initiation rates around 70%. Regimens selected for first-line therapy are diverse between countries, and the WHO-recommended regimen is not preferred in most countries. AZT + 3TC is still the preferred backbone, protease inhibitors are frequently used as third
drug and a few patients initiate integrase inhibitors. Standardization of first-line regimens is warranted in Latin America.

http://dx.doi.org/10.7448/IAS.19.2.21021

**O225**

**Alarming increase of transmitted drug resistance to first-line HIV regimen in Aruba**

L Marije Hofstra1; Elena Sanchez Rivas2; Leonie Bank1; Tania Mudrikova3; Tulio De Oliveira4; Jaclyn de Kort2; Karina Kelly2 and Annemarie Wensing1

1University Medical Center, Medical Microbiology and Virology, Utrecht, Netherlands. 2Horacio E. Oduber Hospital, Internal Medicine, Aruba. 3University Medical Center, Internal Medicine, Oranjestad, Aruba. 4University Medical Center, Medical Microbiology and Virology, Utrecht, Netherlands. 5University of KwaZulu-Natal, Africa Centre for Health and Population Studies, Mtubatuba, South Africa

**Introduction:** The HIV epidemic in Aruba is growing. Recently, genotypic resistance testing in clinical practice showed a worrying increase of the resistance mutation K103N in reverse transcriptase, which generates high-level resistance to the current first-line NNRTI regimens. We set out to investigate whether these patients were therapy-naïve or treated.

**Methods:** HIV-1 pol genotypic sequence analysis was performed for 127 patients of the Horacio E. Oduber Hospital between 2010 and 2015. Baseline testing was performed in 100 patients for 27 patients, resistance testing was only done during therapy failure. Transmitted drug resistance was determined using the WHO list [1]. Phylogenetic analysis included 147 subtype-B sequences from the Netherlands (n = 220) and the top-10 most similar sequences selected via BLAST (n = 145). A maximum-likelihood phylogenetic tree was constructed (GTR-model, 1000 replicates, MEGA6). Clinical and virological data were retrieved from patient records.

**Results:** Most patients were male, with a median age of 40 years, from Aruba, who indicated to be infected in Aruba through sexual contact (Table 1). Twenty per cent of patients presented with an AIDS-defining illness. Transmitted drug resistance to NRTIs (n = 2) or protease inhibitors (n = 2) was low, but the prevalence of K103N in newly diagnosed patients who received baseline resistance testing was 32% overall and increased from 33% in 2014 (8/24) to 48% in 2015 (12/25). K103N was also detected in 60% (16/27) of patients who were only tested during therapy failure, although two patients were not exposed to NNRTI regimens. Phylogenetic analysis revealed that K103N was transmitted to therapy-naïve patients via at least six distinct introductions. One introduction resulted in a large cluster of 36 men. Within this cluster, 73% (24/33) of therapy-naïve patients had K103N. Of those in the cluster without K103N at baseline, four patients presented late, thus reversion of K103N to wild type in the absence of drug pressure cannot be excluded. The majority of this cluster was diagnosed in 2014/2015 (n = 21), of which eight patients had a recent infection based on a recent negative test.

**Conclusions:** The prevalence of the resistance mutation K103N in therapy-naïve patients in Aruba has increased to an alarming level. This is only partly explained by clustered transmission. Although baseline resistance testing has now been implemented routinely, detection of K103N may still fail due to reversion to wild type. In a setting with such high rates of transmitted resistance, it should be considered to adapt to the standard first-line NNRTI regimen.

**Reference**

1. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4(3):e4724.

http://dx.doi.org/10.7448/IAS.19.2.21022

**O226**

**High loss to follow-up among patients with HIV diagnosis during hospitalization**

Mariana Kundro; Sofie Terwel; Guillermo Viloria; Javier Toibaro and Marcelo Losso

Hospital JM Ramos Mejia, HIV Unit, Buenos Aires, Argentina

**Introduction:** There are limited data exploring the retention in care of patients who are diagnosed with HIV in circumstances of...
hospitalization. Our objective was to assess the rates and factors associated with lost to follow-up (LFU) in patients that were diagnosed in our centre during a hospitalization in comparison with individuals who came voluntarily for testing.

**Materials and methods:** All adult patients with a new HIV diagnosis between January 2002 and July 2014 were included. LFU was defined as patients who did not attend any visit and retention in care as patients with two or more visits in the first year after HIV diagnosis. Moreover, we also examined the proportion of patients that attended only one visit within the year after diagnosis. Logistic regression models were used to evaluate factors associated with LFU.

**Results:** A total of 1092 patients were included (27.7% female, 10.1% transgender), of whom 244 (22.3%) were diagnosed in circumstances of hospitalization (68.3% because of AIDS defining illness). About 10.2% (25/244) of patients died during hospital stay and 6.3% (14/219) were rehospitalized before six months from hospital discharge and were excluded from final analyses. Median CD4+ was 110 cell/mm³ (IQR 37–246) for hospitalized patients versus 372 (IQR 235–549) for ambulatory individuals. About 19.2% of patients with HIV diagnosis during hospitalization were LFU, 13% had at least one visit after discharge and 67.1% were retained in care, whereas only 1.92% of ambulatory patients were LFU, 24.2% attended one visit and 73.8% were retained in care. Factors associated with LFU were cocaine use (OR 3.76; CI 95% 1.07 to 7.12; p: 0.03), alcohol abuse (OR 6.06; CI 95% 1.48 to 24.8; p = 0.01) and HIV diagnosis under circumstances of hospitalization (OR 18.14; CI 95% 9.05 to 36.3; p < 0.001), whereas sex, age and AIDS at diagnosis were not associated. In a multivariate model including sex, age, year of diagnosis, alcohol abuse, cocaine use, homosexual transmission and HIV diagnosis during hospitalization, only the last two factors remained as independent factors associated with LFU.

**Conclusions:** The proportion of HIV-infected patients LFU after diagnosis during hospitalization is high. These results highlight the need to implement strategies focused to engage these individuals shortly after hospital discharge.

http://dx.doi.org/10.7448/IAS.19.2.21082

---

**O23 - PUBLIC HEALTH PERSPECTIVES IN HIV**

**O231**

**Elimination of MTCT in the Americas: where are we?**

Massimo Ghidinelli

Pan American Health Organization, Washington, DC, USA

In 2010, PAHO Member States adopted, by resolution, the Strategy and Plan of Action for the Elimination of Mother-to-Child Transmission (EMTCT) of HIV and Congenital Syphilis (CS). Objectives of the plan are (a) to reduce mother-to-child HIV transmission rate to 2% or less; (b) to reduce the incidence of MTCT of HIV to 0.3 cases or less per 1000 live births; (c) to reduce the incidence of CS to 0.5 cases or less (including stillborn infants) per 1000 live births. The resolution called on Member States to give priority to the EMTCT of HIV and syphilis and to develop and execute national plans towards the elimination goals. Significant progress has been made by the region with 17 countries reporting data compatible with the dual elimination by the end of 2014. The rate of MTCT of HIV in Latin America and the Caribbean (LAC) decreased 50% between 2010 and 2014, from 14% to 7%. These data are in line with antiretroviral therapy coverage in HIV-positive pregnant women in LAC, which increased from 56% in 2010 to 81% in 2014. In 75% of the countries, reported MTCT transmission of HIV is under 4%. However, still 17,400 cases of CS were reported in 2014 in the Americas, at a rate of 1.3 cases per 1000 live births. On the other hand, services for HIV and syphilis are becoming firmly integrated in prenatal healthcare, and the EMTCT goals increasingly perceived as quality markers of maternal and child care services. PAHO is proposing that the well-established EMTCT platform for HIV and syphilis in the region could be used to leverage other MTCT infections relevant to public health, such as hepatitis B virus and Chagas disease in endemic areas.

http://dx.doi.org/10.7448/IAS.19.2.21023

---

**O232**

**Cuba EMTCT achievement: How Cuba got there first?**

Maria Isela Lantero

National STI/HIV/AIDS Program, Havana, Cuba

The Cuban HIV/AIDS Prevention and Control Program was conceived based on well-known public health approaches applied in the country for disease prevention and control. Use was made of previous experiences in the control of sexually transmitted infections, and actions were implemented for the early diagnosis of cases, their epidemiological investigation, partner reporting, education of the population and availability of prevention, care and treatment services for those affected. Almost 30 years later, these strategies still exist and have been resized and adapted to each point in the evolution of the epidemic. Our Maternal and Infant Care programme constitutes the platform for the prevention of maternal and congenital syphilis and HIV transmission. Care comprises follow-up of the health status of pregnant women, including the performance of serological tests for syphilis and HIV for them and their sexual partners. Access to prenatal care that includes actions to prevent mother-to-child transmission of HIV, specialized HIV care, antiretroviral treatment and support for people living with HIV network is guaranteed. In the last four years, the annual rate of congenital syphilis has ranged between 0 and 0.04 per thousand live births and the annual rate of mother-to-child transmission of HIV under 2%. Considering these results, we officially requested validation by the Pan American Health Organization and the World Health Organization, and after completing each step established by the regional strategy, Cuba became the first country in the world to receive validation from the World Health Organization that it has eliminated mother-to-child transmission of HIV and syphilis.

http://dx.doi.org/10.7448/IAS.19.2.21024

---

**O31 - WOMEN AND CHILDREN**

**O311**

**Gender-specific issues for HIV-positive women**

Sharon Walmsley

Clinical Research, Immunodeficiency Clinic, Toronto Hospital, and Department of Medicine, University of Toronto, Toronto, ON, Canada

More than half of the HIV-positive population are women. There is limited gender-specific research. In this lecture, I will discuss antiretroviral therapy and the special issues that women need to consider in terms of drug interactions with oral contraceptive agents, risk during pregnancies and comorbidities such as osteoporosis with age. I will also discuss some of the specific issues related to HIV and women, which include human papillomavirus (HPV) infection, the role of the HPV vaccine and other considerations for women ageing with HIV and the impact of the menopause.

http://dx.doi.org/10.7448/IAS.19.2.21025
O312
Gender-specific issues for HIV-positive women: the regional perspective
Alícia Pileinunz
Clinica Especializada Condesa Iztapalapa, Mexico City, Mexico

According to UNAIDS, 31% of adults living with HIV in Latin America are women. HIV transmission among Latin American women occurs mostly through heterosexual contact (96.7%), and in the vast majority of cases, the source of infection is the woman’s stable partner. The existing scientific literature on HIV in Latin American women has primarily focused on populations of women who are considered to be “high risk”: migrants, sex workers, drug users and women in prison. Despite evidence to the contrary, monogamous women with stable partners are often not considered to be at risk for HIV. Timely diagnosis among women is not only crucial in terms of their own prognosis, but it also implies the first step for prevention of HIV mother-to-child transmission. However, HIV testing coverage during pregnancy in the region is currently around 66%, and in some countries declines to proportions as low as 30%. On the other hand, some studies conducted in Latin American countries have shown that women are often diagnosed in advanced stages of HIV infection, many of them due to missed opportunities of timely diagnosis. Women’s vulnerability to HIV infection involves diverse factors, including biological as well as socio-anatomical and policy related aspects. Some of these factors may also represent barriers to healthcare access, linkage to care and antiretroviral treatment. Many countries still lack tailored interventions and strategies for HIV prevention and care in female populations. Interdisciplinary approaches are needed to adequately take care of this particular epidemic.

http://dx.doi.org/10.7448/IAS.19.2.21026

O313
Improving prevention of mother-to-child transmission of HIV outcomes in Haiti from 1999 to 2014: monotherapy to Option B+

Marie Marcelle Deschamps1; Deanna Jannat-Khah2; Jerry Bonhomme2; Vanessa Rouzier4; Pierrot Julma5; Christian Perodin5; Jean William Pape6 and Margaret McNairy3

1Centres GHESKIO, Women’s Health, Port Au Prince, Haiti. 2Weill Medical College of Cornell University, International Medicine, New York, USA. 3Centres GHESKIO, Obstetrics, Port-au-Prince, Haiti. 4Centres GHESKIO, Pediatrics, Port Au Prince, Haiti. 5Centres GHESKIO, Data Management, Port Au Prince, Haiti. 6GHESKIO Centers, Executive Director, Port-au-Prince, Haiti

Introduction: Haiti has one of the highest vertical transmission rates in the Americas. We assessed outcomes of prevention of mother-to-child transmission (PMTCT) care across changes in national guidelines including Option B+, at the largest PMTCT programme in Port-au-Prince over the past decade.

Methods: Data from all HIV-positive women enrolling in PMTCT care at GHESKIO from January 1999 through July 2014 were included. PMTCT cascade steps included enrolment in PMTCT care, receipt of antiretroviral (ARV) prophylaxis or antiretroviral therapy (ART) prior to delivery, infant born alive, infant enrolment in PMTCT care, infant receipt of HIV diagnostic test and infant HIV diagnosis. Outcomes were compared across programme period 1 (1999 to 2004, monotherapy), 2 (2005 to 2009, dual therapy), 3 (2010 to 2012, triple therapy) and 4 (Oct 2012 to 2014, Option B+). Median time from PMTCT enrolment to care and lost to follow up were compared across programme periods.

Results: A total of 3737 HIV-positive women accounted for 4665 unique pregnancies. Median age was 27 years; 66% were married, and 76% earned <51/day. Median maternal CD4 at time of PMTCT enrolment was 494 cells/μL (IQR 328–691). 3501 pregnancies (75%) received ARV/ART prior to delivery, of whom the proportion receiving ART increased from 6% to 100% in periods 1 to 4. Median time to ARV/ART start after mother enrolment in PMTCT decreased from 24 days in periods 1 to 2 to 0 days in period 4. Among 4665 pregnancies, 3414 (73%) had an infant born alive, of whom 3218 (94%) enrolled in PMTCT care. A total of 2955 (92%) infants had complete HIV testing with 161 HIV-infected infants for a 5.5% transmission rate (varying from 9.9%, 4.6%, 5.8% and 3.6% in periods 1 to 4, respectively). Transmission during 2010, after the historic earthquake, was 8.5% as compared to 4.2% in 2009 and 4.6% in 2011. The greatest loss of patients across all periods was among women prior to infant delivery, with median time to loss decreasing from 105 to 31 days in periods 1 to 4. A total of 18% (178/1004) of these women who were lost to follow up had only one PMTCT visit prior to loss. Among 161 HIV-infected infants at 12 months after birth, 71 (44%) were alive in care, 38 died (23%) and 52 lost (32%).

Conclusions: Transmission rates have dramatically declined in this PMTCT programme in Haiti over the past decade, particularly under the era of Option B+. Interventions are needed to retain women and their infants within and after delivery period in order to achieve HIV elimination.

http://dx.doi.org/10.7448/IAS.19.2.21027

O314
Paediatric HIV cascade: from maternal PMTCT to infant ART initiation – improvements over 15 years of scale up in Haiti

Vanessa Rouzier1; Marie Marcelle Deschamps2; Deanna Jannat-Khah2; Jerry Bonhomme2; Pierrot Julma5; Christian Perodin5; Jean William Pape6 and Margaret McNairy3

1GHESKIO Centers, Pediatrics, Port-au-Prince, Haiti. 2GHESKIO Centers, Women’s Health, Port-au-Prince, Haiti. 3Weill Cornell Medical College, Global Health, New York, USA. 4GHESKIO Centers, Obstetrics, Port-au-Prince, Haiti. 5GHESKIO Centers, Pediatrics, Port-au-Prince, Haiti. 6GHESKIO Centers, Executive Director, Port-au-Prince, Haiti

Introduction: Haiti has one of the highest vertical transmission rates in the Americas. We assessed HIV-infected infant outcomes across the paediatric HIV care cascade over a decade of changes in national guidelines in the largest prevention of mother-to-child transmission (PMTCT) and paediatric HIV programme in Port-au-Prince.

Materials and methods: Data from all HIV-infected infants born to women enrolling in PMTCT care at GHESKIO clinic from January 1999 through December 2014 were included. Prior to 2009, HIV infection was confirmed in <18-month olds by two positive HIV-RNA (EasyQ) assays, or one HIV-RNA plus one positive p24 antigen assay, or with a positive HIV ELISA in children >18 months old. Starting in 2009, HIV DNA PCR was diagnostic. Retention across the infant HIV care cascade was compared before and after changes in national guidelines for infant ART eligibility from 1999 to 2008 and from 2009 to 2014.

Results: A total of 3737 HIV-infected women accounted for 4665 unique pregnancies, with 2955 infants completing HIV testing. A total of 161 (5.5% transmission) were HIV-infected. Sixty per cent were female; 12% weighed <2500 g at birth and 50% were delivered in a hospital setting. Median maternal age was 27 years; median maternal CD4 count at PMTCT enrolment was 399 cells/μL (IQR 288–576); and 21% had WHO Stage III/IV symptoms. From 1999 to 2008, 71 HIV-infected infants were diagnosed and 69 (96%) returned for
test results, of whom 44 (64%) had CD4 testing. In this period, 38 were eligible (86%) and 19 (50%) initiated ART. Seven eligible infants died prior to ART initiation. Among the 6 ART-ineligible patients, 3 remain alive in care with CD4 > 1000 cells/L and 3 are lost to programme. From 2009 to 2014, 89 HIV-infected infants were diagnosed and 78 (88%) returned for test results, of whom 77 (99%) had CD4 testing. All 77 (100%) were ART-eligible and 76 (99%) initiated ART.

**Conclusions:** Performance of the infant HIV care cascade since 2009 illustrates that improvements in infant diagnosis, prompt initiation on antiretroviral therapy, and retention in care can be achieved. Point of care infant diagnostics could help reduce loss prior to infant test results return, currently the largest gap in the cascade.

http://dx.doi.org/10.7448/IAS.19.2.21028
P001
Use of social networking applications (apps) and meeting sites in patients with acute HIV infection in a specialized clinic in Mexico City

Jeremy Bernardo Cruz 1; Adriana Harumi Hirata 1; Edgardo Hamid Vega 1; Valeria Daniela Ferreya 1; Carolina Rocabert 1; Victor Rodriguez 2 and Andrea Gonzalez 2
1Clinica Especializada Condesa, Mental Health, Mexico City, Mexico.
2Clinica Especializada Condesa, Coordination VIH Program Mexico City, Mexico, Mexico.

Introduction: Acute phase of HIV infection is a crucial moment; from 2 to 3 weeks after infection, exponential growth of the virus occurs and the person is most infectious, knowing the risks involved [1,2]. We observed a significant impact of applications among men who have sex with men (MSM) and meeting places in sexual health, and use of these applications leads to a greater likelihood of having unprotected sex and spread of disease by sexual transmission [3].

Materials and methods: Semistructured interview about using applications and meeting places in the last three months before diagnosis was applied. Data were collected from 2014 to 2016. Categorical variable frequencies and percentages for the means and standard deviations continuous variables were calculated.

Results: Eighty subjects were reported with acute phase of HIV infection. The average age was 28.11 years (± 8.09), single 68.7% (N = 55), with partner 31.3% (N = 25) of which 48% had discordant couple (N = 12). Years of study 13.5 (± 3.04), employed 46.3% (N = 37), student 20% (N = 16) and 18.7% unemployed (N = 15). On the sexual position, 72.5% (58) were active/passive, 15% (12) were active and 12.5% (10) were passive; 85% uncircumcised. First sexual intercourse was during 18.8 years (± 21.2). SP in the last three months was 8.3 (± 3.04), employed 46.3% (N = 37), student 20% (N = 16) and 18.7% unemployed (N = 15). On the sexual position 72.5% (N = 58) were reported as active/passive, 15% (N = 12) as active and 12.5% (N = 10) as passive. 85% uncircumcised. First sexual intercourse was during 18.8 years (± 17) and sexual partners (SP) along life 129.8 (± 292). SP in the last three months was 8.3 (± 3.04), 56.25% (N = 45) of the total sample reported no condom use with sexual partners an average of 4.3 with no condom was used. The main cause of non-use was impulsiveness in 41.25% (N = 33) followed by trust between partners 32.5% (N = 26); 28.8% (N = 25) reported using applications. Grindr was used in 60.8% (N = 14), Manhunt and Facebook 13.4% (N = 3) each; 52.1% (N = 12) reported using more than one application and 17.4% (N = 4) more than two. The average contact pairs obtained was 15.21 (± 29.7). With regard to meeting places 37.5% (N = 30) goes to meeting places; 50% (N = 15) goes to more than one meeting place and 13.3 (N = 4) are going to more than two. Attending vapours/sauna 50% (N = 15) and orgies 26.6% (N = 8).

Conclusions: This is the first study using applications in a population of newly infected patients in Mexico City. Knowing risk sites allows preventive policies and procedures to risk behaviours.

References
1. Nicola Z, Pilcher C. Diagnosis in management of acute HIV infection. Infect Dis Clin N Am. 2007;21:19–48.
2. Van Kesteren N, Hosphers H, Kok G. Sexual risk behavior among HIV positive men who have sex with men: a literature review. Patient Educ Couns. 2007;65:5–20.
3. Lehmill J, Loenger M. Social networking smartphone applications and sexual health outcomes among men who have sex with men. PloS One. 2014:9.

http://dx.doi.org/10.7448/IAS.19.2.21029

P002
Sexual risk behaviours among MSM with acute HIV infection in a specialized clinic in Mexico City

Adriana Harumi Hirata 1; Jeremy Bernardo Cruz 1; Edgardo Hamid Vega 1; Valeria Daniela Ferreya 1; Carolina Rocabert 1; Victor Rodriguez 2 and Andrea Gonzalez 2
1Clinica Especializada Condesa, Mental Health, Mexico City, Mexico.
2Clinica Especializada Condesa, Coordination VIH Program Mexico City, Mexico, Mexico.

Introduction: Acute phase of HIV infection is a crucial moment of infection to the spread of the virus [1,2]. Weeks 2–3 after infection exponential growth of the decrease in viral load and CD4 occurs. This reported in the literature that sexual risk behaviours as traumatic sex, receptive anal intercourse, active ulcerative disease, sex work, drug use and regular multiple sexual partners. In men, the risk factors have been associated with who are not circumcised [3].

Methods: Semistructured interview about risky sexual behaviour and substance use self-report in the three months prior to HIV diagnosis is applied. Categorical variable frequencies and percentages for the means and standard deviations continuous variables were calculated.

Results: Eighty subjects were reported with acute HIV. The average age was 28.11 years (± 8.09), single 68.7% (N = 55), with partner 31.3% (N = 25) of which 48% had discordant couple (N = 12). Years of study 13.5 (± 3.04), employed 46.3% (N = 37), student 20% (N = 16) and 18.7% unemployed (N = 15). On the sexual position, 72.5% (58) were active/passive, 15% (12) were active and 12.5% (10) were passive; 85% uncircumcised. First sexual intercourse was during 18.8 years (± 21.2). SP in the last three months was 8.3 (± 3.04), 56.25% (N = 45) of the total sample reported no condom use with sexual partners an average of 4.3 with no condom was used. The main cause of non-use was impulsiveness in 41.25% (N = 33) followed by trust between partners 32.5% (N = 26); 28.8% (N = 25) reported using applications. Grindr was used in 60.8% (N = 14), Manhunt and Facebook 13.4% (N = 3) each; 52.1% (N = 12) reported using more than one application and 17.4% (N = 4) more than two. The average contact pairs obtained was 15.21 (± 29.7). With regard to meeting places 37.5% (N = 30) goes to meeting places; 50% (N = 15) goes to more than one meeting place and 13.3 (N = 4) are going to more than two. Attending vapours/sauna 50% (N = 15) and orgies 26.6% (N = 8).

Conclusions: This is the first report in Mexico of sexual behaviours in persons with acute infection. Knowing the sexual behaviour that acute patients have will allow us to make strategies to prevent the spread of HIV.

References
1. Nicola Z, Pilcher C. Diagnosis in management of acute HIV infection. Infect Dis Clin N Am. 2007;21:19–48.
2. Van Kesteren N, Hosphers H, Kok G. Sexual risk behavior among HIV positive men who have sex with men: a literature review. Patient Educ Couns. 2007;65:5–20.
3. Zou H, Prestage G, Fairley CK, Grulich AE, Garland SM, Hocking JS, et al. Sexual behaviors and risk for sexually transmitted infections.
A randomized, double-blind comparison of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF), each co-formulated with elvitegravir, cobicistat and emtricitabine (E/C/F) for initial HIV-1 treatment: week 96 results

David Wohl1; Shinichi Oka2; Nathan Clumeck3; Amanda Clarke4; Cynthia Brinson5; Karen Tashima6; José Arribas7; Antoine Chéret8; Jason Brunetta9; Paul Sax10; Lijie Zhong11; Moupal Dass12; Marcelo Laurido12 and Marshall Fordyce12

1Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA. 2National Center for Global Health and Medicine, Tokyo, Japan. 3Division of Infectious Diseases, Saint-Pierre University Hospital, Brussels, Belgium. 4Brighton and Sussex Medical School, Brighton & Sussex University Hospitals NHS Foundation Trust, Brighton, UK. 5Central Texas Clinical Research, Austin, TX, USA. 6Alpert Medical School of Brown University, Providence, RI, USA. 7Hospital La Paz, Madrid, Spain. 8Tourcoing Hospital, Paris, France. 9University of Toronto, Toronto, Canada. 10Harvard Medical School, Boston, USA. 11Biostatistics, Gilead Sciences, Foster City, CA, USA. 12HIV Clinical Research, Gilead Sciences, Foster City, CA, USA. 13Public Health and Medical Affairs, Gilead Sciences, Foster City, CA, USA.

Introduction: Two international, randomized, double-blind, phase 3 trials in distinct regions directly compared TAF versus TDF, each co-formulated with elvitegravir/cobicistat/emtricitabine (E/C/F). At week 48, E/C/F/TAF met the primary objective of non-inferior efficacy with improved renal and bone secondary safety endpoints compared with E/C/F/TDF. We describe longer-term follow-up of efficacy, safety and tolerability endpoints through week 96.

Materials and methods: Antiretroviral (ARV) naïve participants were randomized 1:1 to receive E/C/F/TAF (TAF) or E/C/F/TDF (TDF). Week 96 viral suppression (HIV-1 RNA <50 c/mL) by FDA snapshot analysis, pre-defined bone and renal safety, and tolerability endpoints are reported.

Results: A total of 1733 subjects were randomized and treated: 15% women, 43% non-white and 23% viral load (VL) >100,000 c/mL. Median baseline characteristics: age 34 years, CD4 count 405 cells/µL and VL 4.58 log10 c/mL. Virologic suppression (HIV-1 RNA <50 c/mL) was 86.6% (TAF) and 85.2% (TDF) (difference 1.5%; 95%CI [−1.8, 4.8%], p = 0.36). Viral outcomes did not vary by age, sex, geography or baseline CD4/ VL. Mean (SD)% decrease in BMD was significantly less in the TAF group for both lumbar spine (−0.96 (3.72) vs. −2.79 (3.92), p < 0.001) and total hip (−0.67 (3.89) vs. −3.28 (3.97), p < 0.001). As shown in Table 1, renal safety endpoints favoured TAF. There were greater increases in lipids in the TAF arm versus TDF but no difference in rate of initiation of lipid-modifying agents (TAF: 3.8% vs. TDF: 4.4%). There were no cases of renal tubulopathy in the TAF arm versus two on TDF, including one that led to discontinuation.

Conclusions: Through week 96, rates of virologic suppression were high and similarly maintained in both the TAF and TDF groups. E/C/F/TAF continued to have a statistically superior bone and renal safety profile compared with E/C/F/TDF. These longer-term data support the use of E/C/F/TAF as a safe, well-tolerated and durable regimen for initial and ongoing HIV-1 treatment.
Results: Of 1733 patients treated, 203 were ≥50 years randomized to E/C/F/TAF and 114 to E/C/F/TDF. Baseline viral load, CD4 counts, renal laboratories and BMD were similar. Adverse events leading to discontinuation were 1.1% for TAF versus 9.1% for TDF, similar to efficacy in the entire study population. Mean change in estimated glomerular filtration rate at week 48 was −5.8 mL/min for E/C/F/TAF versus −11.7 mL/min for E/C/F/TDF (p = 0.010). As shown in Figures 1 and 2, subjects ≥50 years had significantly improved renal tubular profiles with E/C/F/TAF versus E/C/F/TDF. Mean decrease in BMD was significantly less in the E/C/F/TAF versus E/C/F/TDF arm; spine (−1.47% vs. −2.77%, p = 0.011); hip (−0.31% vs. −2.52%, p < 0.001).

Conclusions: Among subjects ≥50 years of age, those receiving 48 weeks of E/C/F/TAF had comparable efficacy and improved bone and renal safety compared with those on E/C/F/TDF, as previously demonstrated in the overall study population. These findings demonstrate an important safety improvement of TAF relative to TDF in patients 50 years and older, which is of particular importance as the population living with HIV ages and experiences more non-AIDS-related co-morbidities.

http://dx.doi.org/10.7448/IAS.19.2.21032

P006
Co-morbidities in a sample of HIV-positive adults in Puerto Rico
Carlos E Rodriguez-Diaz1; Jorge Santana2; Edda I Santiago-Rodriguez3; Gerardo G Jovet-Toledo2; Lourdes Irizarry-Gonzalez2; Yemile Ron-Suarez4; Juan Carlos Orengo4; Felipe Arbelaez4 and Homero Monsanto5
1University of Puerto Rico-Medical Sciences Campus, School of Public Health, Social Sciences Department, San Juan, Puerto Rico. 2University of Puerto Rico-Medical Sciences Campus, School of Medicine, AIDS Clinical Trial Unit, San Juan, Puerto Rico. 3University of Puerto Rico-Medical Sciences Campus, School of Public Health, Center for Sociomedical Research and Evaluation, San Juan, Puerto Rico. 4Merck & Co., Inc., Merck, Carolina, Puerto Rico. 5Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Infectología, Mexico City, Mexico. 6Facultad de Medicina, Universidad Nacional Autónoma de México, División de Investigación, Mexico City, Mexico.

Introduction: Despite expansion of universal access to antiretroviral therapy (ART) in Mexico, AIDS mortality has remained constant. Recent data show heterogeneity in AIDS mortality by state and gender pointing to health inequities within the country. Here we describe the causes and time to death in HIV-positive subjects in Mexico City.

Materials and methods: We obtained data from death certificates (2012–2014) from Mexico City’s Ministry of Health (MoH). We included certificates in which HIV infection was listed. Causes of death were ICD-coded. We obtained all-cause mortality by age groups from the National Institute for Statistics, Geography and Informatics. We evaluated socio-demographic characteristics, causes of death and time to death after HIV diagnosis by gender. We estimated the proportion of deaths from all-deaths by age, gender and borough. We fit logistic models to determine factors related to early mortality (EM, deaths occurring the first year after diagnosis).

Results: There were 1602 registered deaths in HIV-positive subjects in Mexico City (2012–2014). Sixty-six per cent were early deaths. Women accounted for 27% of deaths, were older at death than men (57 years vs. 41 years), were less frequently single (22% vs. 50%) and were less educated. Twenty-four per cent of women died in the first month after diagnosis in contrast to men (50%). Twenty-six per cent of women died more than five years after the HIV diagnosis, while 12% of men did. Most deaths (74%) among men were early deaths and concentrated in a few boroughs. Boroughs with the highest number of deaths showed a north–south geographic pattern that did not follow the size of the population or its overall mortality. The most common causes of death were AIDS-defining opportunistic infections (OI), respiratory illnesses, liver disease and non-AIDS-related infections. Male gender, younger age (<20 years), single and lack of social insurance were independent risk factors associated with EM.

Conclusions: A large proportion of deaths in HIV-positive individuals occur within the first year of diagnosis, which might be explained by late diagnosis and poor linkage to care. We observed differences in socio-demographic, geographic and clinical profiles across age groups and gender in HIV-positive individuals that died in Mexico City in 2012–2014. Most deaths occur early in young, uninsured, single men in two city areas. More deaths among women occurred due to chronic diseases late after diagnosis. EM accounts for most of the deaths among uninsured people. Addressing late diagnosis and lack of linkage to care could contribute to reduce AIDS-associated deaths in Mexico City even further.

http://dx.doi.org/10.7448/IAS.19.2.21033
Introduction: Puerto Rico (PR) is among the areas with the highest estimated rates of people with HIV in the United States. Despite the availability of epidemiologic data, there is a lack of real-world information that can help in understanding the co-morbidities of people with HIV in PR. The objective of this study was to describe common co-morbidities among HIV-positive adults who attend treatment clinics in PR.

Methods: An exploratory, retrospective, cross-sectional study was conducted at five clinics that provide services to people with HIV in PR. A random sample of medical records was reviewed from HIV-positive adult patients. Patient with HIV-related illness and pregnant women were excluded from the sample. Descriptive statistics were used to summarize patient demographics, morbidity and clinical characteristics. Multivariate analyses were conducted to explore differences by age and sex.

Results: A total of 250 (179 men and 71 women) medical records were reviewed. The mean age was 47.9 years, and in average, they have been living with HIV for nine years. Most (97.6%) had at least one co-morbidity. The most common co-morbidities were dyslipidaemia (men: 60.8%; women: 69.0%) and hypertension (men: 39.6%; women: 46.5%). The most common co-morbidity treatments and supplements were multivitamins, lipid lowering therapy and antihypertensive agents. These remain as the most common treatments after stratifying by sex. Men were more likely to have been diagnosed with alcohol misuse (OR = 4.08), while women were more likely to have been diagnosed with obesity (OR = 2.95), human papillomavirus (OR = 2.80), hypothyroidism (OR = 3.46) and osteoporosis (OR = 9.68). Younger participants (<50 years) were more likely to have alcohol misuse (OR = 2.04), while the older individuals (>50) were more likely to have been diagnosed with dyslipidaemia (OR = 3.21), hypertension (OR = 2.94) and diabetes mellitus (OR = 3.40). Controlling by sex and age, women were more likely to have been diagnosed with obesity (OR = 3.20) and depression (OR = 1.99). Co-morbidities associated with the >50 age group were dyslipidaemia (OR = 3.08), hypertension (OR = 2.85), HPV (OR = 2.55) and diabetes mellitus (OR = 3.33).

Conclusions: This is one the first studies to assess co-morbidities among people with HIV in PR, and one of few among Latino populations within the United States. Consistent with other studies, cardiovascular diseases are common among people with HIV in PR. Findings support the need for awareness and real-world evidence about the necessity of considering the co-morbidities of people with HIV when implementing screening and preventive tests and prescribing drug therapy.

http://dx.doi.org/10.7448/IAS.19.2.21034

P007
Baseline characteristics of a prospective cohort of adult HIV-positive patients in Latin America (LATINA)
Gabriela Rodríguez Loria1; Marcelo Losso2; Luis Mosqueda1; Guillermo Viloria1; Jorge Alave1; Jaime Andrade Villanueva1; Mariana De Paz6; Hector Laplume7 and Waldo Belloso2
1Fundacion Ibis, Research, Buenos Aires, Argentina. 2Cical, Research, Buenos Aires, Argentina. 3Hospital General Ramos Mejia, Immunocompromised Patient, Buenos Aires, Argentina. 4Hospital de Barranco, Infectology, Lima, Peru. 5Hospital Civil de Guadalajara, Infectology, Buenos Aires, Argentina. 6Hospital Italiano de Buenos Aires, Infectology, Buenos Aires, Argentina. 7Hospital Posadas, Infectology, Buenos Aires, Argentina.

Introduction: Though HIV epidemics are not decreasing in most Latin American countries, there is little information about the baseline demographics, clinical status at diagnosis and therapeutic course of patients initiating follow-up. LATINA Cohort has already provided information about these issues in its retrospective component. We present here the first analysis of its prospective component based upon sites from three countries.
**Material and methods**: The cohort is built by a multinational Executive Committee and National Coordinating Centers in charge of local logistics, identification and inclusion of contributing sites. From initial involvement of sites who participated in the retrospective cohort, we moved forward to include new sites specializing in HIV ensuring data quality. The prospective cohort started gathering data in September 2013 from six sites and progressed to the current 12 distributed in Argentina (nine sites), Mexico (two sites) and Peru (one site). Data presented here correspond to patients enrolled until March 2015. Inclusion criteria were recent HIV diagnosis (within one year) and at least two prior visits to the site in order to ensure commitment. Data collection was performed through a website (www latina.cical.org) including data obtained in standard of care visit. Diagnosis for AIDS defining diseases was based on CDC criteria, and standardized criteria were developed by the Executive Committee for serious non-AIDS events. Database was periodically checked for incompleteness and consistency. All data were consolidated in an Access database and analyzed using Statistics V17.

**Results**: A total of 748 patients were included in this analysis of baseline visit; 578 (77%) were from Mexican sites, 158 (21%) from Argentinian and 12 (2%) from Peruvian Site. Characteristics of our cohort were provided in Table 1.

**Conclusions**: Data presented reflects the situation of HIV epidemics, with mostly young males, predominantly men who have sex with men and with a significant proportion of late presenters and self-reported users of alcohol and tobacco. A major limitation of this cohort is selection bias due to convenience sampling. Data quality is acceptable among all participating sites present and constitutes a quite diverse and interesting data set for both continue to follow-up and expansion of its regional representativity.

http://dx.doi.org/10.7448/IAS.19.2.21035

**HIV/HEPATITIS CO-INFECTION**

**P008**

**Ledipasvir/sofosbuvir is safe and effective for the treatment of patients with genotype 1 chronic HCV infection in both HCV mono-and HCV/HIV co-infected patients**

Jorge Santana 1; Mark Sulkowski 2; Curtis Cooper 3; Paul Kwo 4; Douglas Dieterich 5; Sarah E Kleinstein 6; Nelson Cheinquer 7; Michael Saag 8; Jorge Santana 2; Mark Sulkowski 2; Curtis Cooper 4; Sarah E Kleinsteiber 6; Nelson Cheinquer 7; Michael Saag 8; Jorge Santana 2; Mark Sulkowski 2; Curtis Cooper 4; Sarah E Kleinsteiber 6; Nelson Cheinquer 7; Michael Saag 8

1University of Puerto Rico, School of Medicine, San Juan, Puerto Rico. 2Johns Hopkins University, School of Medicine, Baltimore, USA. 3Indiana University, Department of Medicine, Indianapolis, USA. 4Swedish Medical Center, Liver Care Network, and Organ Care Research, Seattle, USA. 5Columbia University, Institute for Genomic Medicine, New York, USA. 6Public Health and Medical Affairs, Gilead Sciences, Sao Paulo, Brazil. 7Medical Affairs, Gilead Sciences, Foster City, CA, USA. 8Clinical Pharmacology, Gilead Sciences, Foster City, CA, USA. 9Clinical Research, Gilead Sciences, Foster City, CA, USA. 10Department of Medicine, Duke University, Durham, USA.

**Introduction**: Current AASLD/IDSA Hepatitis C Guidance states that HCV/HIV-co-infected patients should be treated the same as persons without HIV infection, after recognizing and managing interactions with antiretrovirals (ARVs). We compared the safety and efficacy of the single-tablet regimen of ledipasvir/sofosbuvir (LDV/SOF) in HCV genotype (GT) 1 patients co-infected with HIV-1 in the Phase III ION-4 study with HCV monoinfected GT1 patients in the Phase III ION 1–3 studies.

**Methods**: In the ION-4 study, 327 GT1 HCV/HIV-co-infected patients received LDV/SOF 90/400 mg daily for 12 weeks. In the ION 1–3 studies, 538 GT1 HCV monoinfected patients received LDV/SOF 90/400 mg daily for 12 weeks. This pooled analysis will assess safety and sustained virologic response at week 12 (SVR12). LDV, SOF and GS-331007 exposures in HCV/HIV-co-infected subjects were also compared across ARV regimes, race, SVR12 and to subjects with HCV monoinfection. A genome-wide association study (GWAS) was conducted to identify host genetic determinants of HCV relapse after LDV/SOF therapy in HCV/HIV-co-infected individuals on ARVs.

**Results**: A total of 865 patients were treated with LDV/SOF for 12 weeks in the Phase III ION programme. In ION-4, the overall SVR12 was 96% and relapse rate was 3%. In ION 1–3, the overall SVR12 was 97% and the relapse rate was 2%. SVR12 by treatment history, cirrhosis status, race and GT1 subtype is reported in Table 1. Most common adverse events (>10% reported in any arm) were fatigue, headache, diarrhoea and nausea. There were no clinically relevant differences in pharmacokinetics (PK) of LDV/SOF in HCV/HIV-co-infected subjects compared with HCV monoinfected subjects. GWAS did not reveal significant associations with HCV relapse.

**Conclusions**: In this pooled analysis, the once daily, single-tablet regimen of LDV/SOF for 12 weeks provided high rates of SVR regardless of the presence of HIV infection and is a safe, well-tolerated option for patients with both HCV monoinfection and HCV/HIV co-infection.

http://dx.doi.org/10.7448/IAS.19.2.21036

**P009**

**Ledipasvir/sofosbuvir for 12 weeks in patients co-infected with HCV and HIV-1**

Michael Saag 8; Jorge Santana 2; Mark Sulkowski 2; Curtis Cooper 4; Douglas Dieterich 5; Sarah E Kleinsteiber 6; Nelson Cheinquer 7; Michael Saag 8; Jorge Santana 2; Mark Sulkowski 2; Curtis Cooper 4; Douglas Dieterich 5; Sarah E Kleinsteiber 6; Nelson Cheinquer 7

**Abstract P008 - Table 1. SVR12 by treatment history, cirrhosis status, race and GT1 subtype**

| Study             | ION 1 | ION 2 | ION 3 | ION 1 1–3 (combined) | ION 4 (HIV) |
|-------------------|-------|-------|-------|----------------------|-------------|
| Treatment-naive SVR12 (%) | 210/213 (99) | 102/109 (94) | 208/216 (96) | 418/429 (97) | 138/146 (95) |
| Treatment-experienced SVR12 (%) | 32/34 (94) | 19/22 (86) | 83/87 (95) | 40/42 (95) | 89/90 (99) |
| Cirrhosis SVR12 (%) | 179/179 (100) | 24/24 (100) | 82/86 (95) | 389/403 (97) | 239/250 (96) |
| Non-cirrhotic SVR12 (%) | 188/190 (99) | 78/85 (92) | 165/173 (95) | 431/448 (96) | 215/217 (99) |
| Blacks SVR12 (%) | 142/145 (98) | 20/23 (87) | 43/44 (98) | 130/134 (97) | 74/77 (96) |
| Non-blacks SVR12 (%) | 67/67 (100) | | | | |
| GT 1a | | | | | |
| GT 1b | | | | | |
Abstract P009 – Table 1. Efficacy and reasons for not achieving SVR12 by ARV regimen

| Virologic Response | TDF + FTC + EFV (n = 160) | TDF + FTC + RAL (n = 146) | TDF + FTC + RPV (n = 29) | Overall (n = 335) |
|--------------------|---------------------------|--------------------------|-------------------------|------------------|
| SVR12, n (%)       | 151 (94)                  | 141 (97)                 | 28 (97)                 | 320 (96)         |
| On-Treatment Failure, n (%) | 1 (<1) | 0 | 1 (3) | 2 (<1) |
| Relapse, n (%)     | 8 (5)                      | 2 (1)                    | 0                       | 10 (3)           |
| Other, n (%)       | 0                         | 1 (<2)                   | 0                       | 2 (<1)           |

Sarjita Naik1; John Wolf2; Macky Natha3; Polina German5; Luisa Stamm6; Diana Brainard7 and Susanna Naggie11
1Division of Infectious Diseases, University of Alabama, Birmingham, USA. 2University of Puerto Rico, School of Medicine, San Juan, Puerto Rico. 3Johns Hopkins University, School of Medicine, Baltimore, USA. 4Division of Infectious Diseases, University of Ottawa, Ottawa, Canada. 5Department of Medicine, The Mount Sinai Hospital, New York, USA. 6Columbia University, Institute for Genomic Medicine, New York, USA. 7Public Health and Medical Affairs, Gilead Sciences, Sao Paulo, Brazil. 8Medical Affairs, Gilead Sciences, Foster City, CA, USA. 9Clinical Pharmacology, Gilead Sciences, Foster City, CA, USA. 10Clinical Research, Gilead Sciences, Foster City, CA, USA. 11Department of Medicine, Duke University School of Medicine, Durham, USA.

Introduction: Historically, HIV co-infection was considered a negative predictor of HCV response to treatment with interferon/ribavirin (IFN/RBV). For sofosbuvir-based regimens, HIV/HCV patients have achieved similar sustained virologic response (SVR) rates as HCV monoinfected patients. We evaluated the safety and efficacy of the IFN-free, RBV-free, single-tablet regimen of ledipasvir/sofosbuvir (LDV/SOF) in HCV patients. We evaluated the safety and efficacy of the IFN-free, RBV-free, single-tablet regimen of ledipasvir/sofosbuvir (LDV/SOF) in HCV patients. We evaluated the safety and efficacy of the IFN-free, RBV-free, single-tablet regimen of ledipasvir/sofosbuvir (LDV/SOF) in HCV patients.

Materials and methods: In the ION-4 study, 335 patients with GT1a (75%), GT1b (23%) and GT4 (2%) were enrolled; 82% were male, 61% were white, mean age was 52 (range 26–72), mean baseline HCV RNA was 6.7 log10 IU/mL (range 4.1–7.8), median baseline CD4 count was 662 cells/µL (Q1, Q3 = 469, 823), 20% had cirrhosis, 24% were IL28B CC genotype and 55% had not responded to prior HCV treatment. Overall, the SVR12 rate was 96% (322/335); two patients had on-treatment virologic failure likely due to non-compliance and 10 had virologic relapse after discontinuing treatment. SVR12 was similar among non-cirrhotic (96%) and cirrhotic (94%) patients and also among treatment-naive (94%) and treatment-experienced (97%) patients. SVR12 by ARV regimen is shown (Table 1). AEs occurring in ≥10% of patients were headache (25%), fatigue (21%) and diarrhea (11%). Exposures of LDV, SOF and GS-331007 were comparable across ARV regimens, race and treatment outcome. GWAS did not reveal significant associations with HCV relapse.

Conclusions: The IFN-free, RBV-free, single-tablet regimen of LDV/SOF administered once daily for 12 weeks is highly effective and well tolerated in treatment-naive and experienced, genotype 1 or 4 HCV-infected patients with HIV-1.

http://dx.doi.org/10.7448/IAS.19.2.21037

HIV AND WOMEN INCLUDING MTCT

P010

Improved safety and efficacy of TAF versus TDF single-tablet regimen in HIV-1 treatment-naive women through week 48

| TAF (n = 133) | TDF (n = 127) | p-value |
|---------------|--------------|---------|
| Median baseline HIV viral load (log10 copies/mL) | 4.50 | 4.46 | 0.70 |
| Median baseline CD4 (µL) | 358 | 367 | 0.75 |
| Virologic success at W48, % | 95% | 87% | 0.023 |
| Median change in CD4 (µL) at W48 | 216 | 181 | 0.37 |
| Discontinuation due to treatment-emergent adverse events (AEs), % | 0 | 1.6 | 0.24 |
| Treatment-emergent grade 3 or 4 AEs, % | 9 | 11.8 | 0.54 |
| PRT (proximal renal tubulopathy), n | 0 | 0 | – |
| Median changes in eGFR (mL/min), W48 | –5.4 | –12.6 | <0.001 |
| Median % changes in UPCR (urine protein/creatinine mg/g), W48 | –9.7 | –1.2 | 0.31 |
| Median % changes in UACR (urine albumin/creatinine mg/g), W48 | –4.1 | +8.3 | 0.40 |
| Mean % changes in spine BMD, W48 | –0.959 | –2.912 | <0.001 |
| Mean % changes in hip BMD, W48 | –1.255 | –3.475 | <0.001 |
P011

Pregnancies in adolescents infected with HIV in the state of São Paulo, Brazil: challenges to avoid mother-to-child transmission of HIV and keep these adolescents alive

Maria Aparecida Silva; Carmen Silvia B Domingues and Angela Tayra
São Paulo State Program for STDs and AIDS, STD and AIDS Referral and Training Center, São Paulo State Department of Health, São Paulo, Brazil.

Introduction: Adolescence is the transition between childhood and adulthood. Primary care health units concentrate visits in antenatal care (ANC), child health and chronic diseases, which may prevent adolescents from using these services. Adolescents may only access services when pregnant or with symptoms of a disease, including sexually transmitted diseases (STDs). The aim of this study was to describe AN, time of HIV diagnosis and pregnancy outcome in HIV-positive adolescents in the state of São Paulo (SSP) between 1999 and 2015.

Materials and methods: Descriptive study of 12 to 19 year-old HIV-positive pregnant teenagers, living in SSP, diagnosed with HIV between 1 January 1999 and 30 June 2015. Data source: cases reported to the Disease Information System (Sinan).

Results: 1793 pregnancies were reported in HIV-positive adolescents, about 8% (1793/21,662) of total of the SSP. Pregnancies occurred in 1591 adolescents: 88.3% (1405/1591) had one pregnancy, 10.7% (171/1591) two, and 0.9% (15/1591) three or more. In 43.9% (788/1793) of pregnancies, HIV diagnosis was before AN, 44.3% (795/1793) during AN and 9.0% (162/1793) during or after childbirth; AN occurred in 91.2% (1636/1793) of pregnancies, with 56.8% (929/1636) starting in the 2nd or 3rd trimester; in 74.5% (1335/1793) antiretrovirals were used during AN, in 7.3% (131/1793) not used, and in 18.2% (327/1793) not specified; 56.0% (1004/1793) evolved to caesarean delivery and 26.9% (482/1793) to vaginal delivery; miscarriages and stillbirths accounted for 2.3% (41/1793). Excluding miscarriages, stillbirths and ongoing pregnancies, in 73.3% (1263/1722) intravenous zidovudine was used during childbirth, in 9.9% (171/1722) not used, and in 16.7% (288/1722) not specified.

Conclusions: In this population, the high proportion of pregnancies diagnosed with HIV before AN suggest adolescents are infected by perinatal transmission or with unprotected early sexual activity. The care network must discuss specific strategies of access to services for adolescents, prevention inputs, sexual and reproductive healthcare, including access to long-acting contraceptives. It is important to link and retain this population in HIV services, to improve coverage and adherence to antiretrovirals, reduce viral load and maintain virologic suppression, prevent mother-to-child transmission of HIV and keep these adolescents alive.

http://dx.doi.org/10.7448/IAS.19.2.21039

P012

Case investigation protocol and committee as strategies to reduce and eliminate mother-to-child transmission of HIV: experience of the state of São Paulo, Brazil

Carmen Silvia B Domingues; Maria Aparecida Silva; Angela Tayra; Maria Clara Gianna and Surveillance of Maternal and Infant Mortality
Saúo Paulo State Program for STDs and AIDS, STD and AIDS Referral and Training Center, São Paulo State Department of Health, São Paulo, Brazil. "Department of Health, Sao Paulo State Department of Health, Sao Paulo, Brazil.

Introduction: Although intervention measures to prevent mother-to-child transmission (MTCT) of HIV are available in healthcare services for pregnant women, post-partum women and children, several social, political, economic and individual factors may hinder access of this population to these measures, contributing to the occurrence of cases. In 2014, the National STD/AIDS Department recommended the implementation of state and municipal committees to investigate, discuss and propose measures to reduce and eliminate MTCT of HIV, using a pre-established protocol to identify determinants of the disease. The committees are intra-institutional, inter-institutional, and multidisciplinary bodies with confidential technical performance and educational function, essential for monitoring and evaluating healthcare policies. The state of São Paulo (SSP) proposed using Mother and Child Mortality Committees, given they have already been established and are operating regularly. MTCT has declined in SSP – 538 cases in 1996 and 21 in 2013, by year of birth. The aim of this study was to describe MTCT research results in children under 5 years of age, born in the SSP between 2007 and 2013.
Materials and methods: Descriptive study using research protocol with 67 questions in 3 groups: antenatal, delivery and postpartum/child monitoring [1]. At the conclusion of the protocol, determinants are classified into types of vulnerability: individual-social maternal and program (service or management) for decision making.

Results: The 90 protocols studied 53 cases (58.9%) by individual-social maternal vulnerability, 8 (8.9%) programme-services, 17 (18.9%) in both areas, 9 (10%) under investigation, and 3 (3.3%) despite infection, followed prophylactic measures correctly. Main categories of individual and social vulnerability: 20 cases of drug use (“crack,” alcohol and others), 7 living in the streets and drug use, 17 with low-income and 10 immigrants; for program-service: gaps in prevention measures, search for absences, and improving adherence to antiretroviral drugs. Median maternal age of 30 years, 37.8% were single and 41% housewives.

Conclusions: The success of the national HIV/AIDS policy has reduced MTCT. Currently, determinants of this disease are mainly related to individual and social components of this population and their accessibility to services. Committees can contribute to improve healthcare activities and quality of public policies to overcome these barriers.

Reference
1. http://www.aids.gov.br/sites/default/files/anexos/publicacao/2014/56592/tv_2_pdf_18693.pdf

http://dx.doi.org/10.7448/IAS.19.2.21040

P013
Long-term follow-up of HIV-infected mothers from perinatal and LILAC studies in Buenos Aires, Argentina
Danielle Gladstone1; Silvina Ivalo2; Sharon Nachman1 and Marcelo Losso3
1Stony Brook University Hospital, Pediatric Infectious Disease, Stony Brook, New York, USA. 2Hospital J. M. Ramos Mejia, Immunocompromised, Buenos Aires, Argentina.

Introduction: HIV treatment guidelines updates following the results of the Strategic Timing of AntiRetroviral Treatment (START) study and WHO B+ guidelines have changed antiretroviral (ARV) treatment practices for HIV-infected post-partum women. Factors significant to predicting treatment abandonment (ABND) among these patients differ globally. Our study aim was to evaluate the factors that are associated with ABND in this cohort.

Methods: Retrospective review of charts from all women that participated in either or both the BA perinatal study (2002 - 2007) and the BA LILAC: The longitudinal study in Latin American countries (2008 – 2012) was included. Data collected included patient status at the study completion visit through 31 July 2015, medical indication for ARV treatment, ABND, alcohol (ETOH), smoking or substance use, CD4 nadir and most recent count, hospitalizations, hepatitis co-infection (B/C), opportunistic infections (OIs), change in CDC status, sex industry employment and year last seen in clinic. Associations with the defined outcome were estimated using chi-square analysis.

Results: Of the 150 women (178 pregnancies), charts were available on 108 women. Only 72 out of 150 were still in care through 2015. Of the 51 women recommended to continue ARV post-perinatal/LILAC, age 32, (range 26.2 – 43.7 years, SD 3.75), 27% had B/C, 6% were sex workers, 27% were drug abusers, 13% ETOH, 33% smoked cigarettes and 29% were AIDS defined (41% CDC A). Thirty-seven (72%) abandoned ARV treatment at some point with 40% of those women developing an OI while off-treatment; 57 women did not have an end of study indication for ARVs. On average, they were 27.6 years of age (range 18.49 – 37.38, SD 4.96); 12% had B/C and 5% were sex workers; 23% were drug abusers, 9% ETOH and 36% smoked cigarettes. At the time of completion of their prior study, 94% were CDC A. Forty-one were later recommended to start therapy, of which 71% abandoned therapy. 46% of those recommended to start therapy (post-perinatal/LILAC) but who ABND, developed an OI. Maternal ARV ABND was not predicted by smoking status, ETOH substance use, hepatitis B/C status, HIV status of infant, or prior parity. Being a sex worker (p = 0.03) and CDC C (p < 0.001) were associated with predicting ARV ABND.

Conclusions: In this long-term follow-up study, many women continued in intermittent care despite not taking ARVs; 71 – 72% of these women stopped ARV treatment at least once during the follow-up period despite having an indication to continue treatment. Barriers to retention in care required further evaluation.

http://dx.doi.org/10.7448/IAS.19.2.21041

P014
Implementation gaps for interventions to prevent mother-to-child transmission of HIV in Mexico during 2014
Adriana Villafuerte García1; María del Pilar Rivera Reyes2; Patricia Uríbe Zúñiga3 and Carlos Magis Rodríguez4
1Centro Nacional para la Prevención y el Control del VIH y el sida, Atención Integral, Mexico City, Mexico. 2Centro Nacional para la Prevención y el Control del VIH y el sida, Investigación Operativa, Mexico City, Mexico. 3Centro Nacional para la Prevención y el Control del VIH y el sida, Dirección General, Mexico City, Mexico.

Background: Since the commitment to eliminate the mother-to-child transmission (MTCT) [1,2] of HIV by 2018, the Mexican Health Ministry has generated evidence that contributes to the design of strategies for HIV testing promotion in pregnant women and their linkage to HIV health services. As part of these actions, the current study gives an overview of the gap between the detection and the antiretroviral treatment (ART) access to prevent the MTCT (PMTCT) of the HIV; also, it shows the need to strengthen the monitoring of cases considering the moment of transmission and the timeliness of diagnosis.

Methods: We estimated the number of pregnant women with HIV in 2014 through the UNAIDS Spectrum model. The total detections were obtained from the percentage of screening coverage [3]. The number of pregnant women with HIV who received ARV for PMTCT was obtained from the reports of the HIV Sector Information Group (part of the National Council for the Prevention and Control of AIDS). The perinatal cases from the National Register Cases of AIDS (NRC) were analyzed. We classified the cases according to the year of birth and the diagnosis age. Finally, an estimate of the expected number of cases was performed.

Results: From an estimation of 1,450 pregnant women with HIV in 2014, 59% (n = 856) were detected and 38% (n = 555) received ARV for PMTCT. Likewise, based on the NRC, between 2014 and 2015, 36 children that born in 2014 were diagnosed with vertical HIV transmission. The cases of vertical HIV transmission review from 2004 to 2014 show that on average 32% of these cases were timely diagnosed. The trend was similar in the past 10 years (between 21% and 39%), except in 2014, where there was an increase compared to 2013 (48% vs. 25%). The analysis of the cases according to the birth year showed that the decrease observed, based on the number of diagnostics reported annually, is a reflection of the delay diagnoses but not a reduction in transmission because according to the estimation, 113 cases are finally expected in 2014.

Conclusions: In Mexico, the low coverage of detection and connection to the continuum of care results in a low proportion of pregnant women having access to ART. The Pan American Health Organization recommended surveillance based on case reports to facilitate longitudinal tracking of infected people [4]; however, the gaps make the surveillance partially retrospective, limiting, for now, the possibility of preventing the transmission.
P015
Antiretroviral resistance among pregnant women in São Paulo, Brazil

Giselle Itette Silva López Lopes1; Gabriela Bastos Cabral1; Jaqueline de Souza Cavalcanti1; Geovana Rafaela Silva1; Norberto Camilo Campos2; Camila Rodrigues2; Elaine Monterio Matsuda3 and Luís Fernando de Macedo Brígido4

1Adolfo Lutz Institute, Virology, São Paulo, Brazil. 2NAIC, Clinical Medicine, Carapicuíba, Brazil. 3ARMI Santo André, Clinical Medicine, Santo André, Brazil.

Introduction: Pregnant women living with HIV, either diagnosed during prenatal care or on regular follow-up, may benefit from viral suppression, also essential for reduction of vertical transmission. The aim of the study was to access ARV resistance during pregnancy and the immunological and virological outcome at the time of delivery.

Methods: The study included 86 pregnant women living with HIV, genotyped from 2013 to 2015. Resistance profile was compared to that of 145 women at reproductive age failing ARV in that period. Partial pol was obtained from RNA (nested RT-PCR followed by big fragment sequencing/long-range PCR). The samples were genotyped from 2013 to 2015. Resistance profile was compared to that of 145 women at reproductive age failing ARV in that period.

Results: At genotyping, these pregnant women were at 22 gestational weeks, age 27 years and older, exposed to two ART regimens, viremia 3.39 Log10 and CD4 384 cells/mm3. Only 74% (64/86) had treatment information, 34% (22/64) naïve (age 26 years and older, CD4 354 cells/mm3, viremia 3.73 Log10). Transmitted resistance was observed in 4.5% (1/22) of naïve cases. At delivery, 50% were aviraemic, and overall viremia had significantly lowered to 1.82 (p = 0.003). Comparing treated pregnant women to other women failing ARV, they tended to be younger (28 vs. 38 years and older, p < 0.0001), less exposed to ART (2 vs. 3 regimens, p = 0.003), had a lower viremia (3.20 vs. 4.43 Log10, p < 0.0001) and a higher CD4 (403 vs. 233 cells/mm3, p = 0.0002). Most pregnant women on treatment showed no resistance mutations (65% vs. 25%, p < 0.0001). At delivery, 46% were with undetectable viral load and viremia was also significantly lowered to 1.83 Log10 (p < 0.0001).

Conclusions: This study highlights the need to explore better understand the causes of this performance and the opportunities to improve the PC and the quality of HIV testing and counselling in order to achieve better results in reducing vertical transmission of HIV.
Prevention and Comprehensive Care, Mexico City Ministry of Health, Mexico, Mexico.

Introduction: Timely HIV diagnosis is key to controlling the spread of the epidemic among “Most at Risk Population” groups (MARPs) in Mexico City. Given that the HIV epidemic is concentrated in men who have sex with men, transgender women and male sex workers, groups that traditionally do not seek care at public health facilities, it is imperative to implement HIV diagnosis strategies that not only detect positive cases but also retain them for care.

Materials and methods: The HIV diagnosis strategy implemented by the Condesa Specialized Clinics (CEC) laboratory includes a comprehensive approach to detection of not only HIV but also of other sexually transmitted infections (STIs) such as syphilis, hepatitis B and C, CD4 count and viral load. Rapid testing is applied to HIV and syphilis detection and basal CD4 count, while all the other results are...
Introduction: In Mexico City, about 35,000 men are in prison, distributed throughout eight centres, with an HIV prevalence of 1.0% [1]. Prison inmates that are diagnosed with HIV are then transferred to the Santa Martha Acatitla (SMA) Prison, where they are offered highly active antiretroviral therapy (HAART) and specialized medical care.

Results: During the beginning of 2015, there were 192 patients at SMA, 54.9% of the total of estimated cases (N = 350). During 2014, 4559 HIV tests were performed in all detention centres in Mexico City.

Material and methods: During 2015, several innovative strategies were implemented aimed at prison inmates: in the two largest centres, voluntary HIV testing was offered to inmates by the correctional facility medical staff when they entered the prison. In one centre (the second largest), there was an HIV screening of all the prison population, while in another there was a health fair where HIV testing was offered to inmates as well as their family members. All prison centres received periodic visits of the HIV Mobile Diagnosis Team. The data were collected until 31 October 2015 in order to analyze the impact in the continuum of care of all new diagnosis.

Results: A total of 20,535 HIV tests were performed from 1 January 2015 through 31 October 2015 in all the prison centres in Mexico City (4.5 times of all tests performed in 2014). Fifty-five new cases were diagnosed, along with 22 previously diagnosed cases, with an average CD4 count of 327 cell/ml (SD = 258) (Figure 1). During this time, 56 patients were freed and two died. By 31 October, 216 inmates with HIV were aware of their HIV positive status (61.7% of the total estimated cases), 211 (60.3%) were incorporated to care, 210 (60.0%) retained in care and 204 (58.3%) received HAART. 190 (54.3%) patients had a viral load (VL) of < 200 copies/ml, and 175 (50.0%) had a VL of < 40 copies/ml. 96.7% of the newly diagnosed patients are receiving HAART and 90% of patients on HAART have a VL of < 40 copies/ml (83% with VL < 200 copies/ml) (Figure 2).

Conclusions: The HIV care programme in prisons has achieved two of the goals set by the WHO 90-90-90 initiative. The implementation of new diagnosis strategies has been translated into a significant increase in the number of HIV detections in prisons. The widespread implementation of these strategies in all the prison system of Mexico City may allow us to diagnose 90% of HIV cases among prison inmates.

Reference
1. Gras AN, Badial HF, González RA. Salud pública, VIH/SIDA y derechos humanos en los centros de reclusión. Revista de derechos humanos – defensor. Número 8–Agosto 2013, pp. 13–21.

http://dx.doi.org/10.7448/IAS.19.2.21044
Methods: MSWs recruited from Clínica Condesa HIV Testing Clinic and community sites in Mexico City were tested and treated for STIs (chlamydia, gonorrhoea, syphilis and HIV) and viral hepatitis (hepatitis B and C) at a baseline, 6-month follow-up and 12-month follow-up clinic visits. Participants completed surveys at all visits to document socio-demographic characteristics and health behaviours. We estimated incidence rates and calculated 95% confidence limits using a bias-corrected and accelerated bootstrap method with 1000 replicates. We used mixed effects logistic regression with individual fixed effects to examine unadjusted and multivariable adjusted time-varying predictors of incident STIs (excluding HIV in order to retain participants with prevalent HIV infection).

Results: Among 227 eligible participants, the median age was 24 and baseline HIV prevalence was 32%. Incidence rates were as follows: HIV (5.28 per 100 person-years (PY); 95% 2.25, 11.75), chlamydia (4.63 per 100 PY; 95% 2.10, 9.09), gonorrhoea (3.92 per 100 PY; 95% 1.88, 7.58), active syphilis (12.44 per 100 PY; 95% 8.17, 18.51), hepatitis B (2.13 per 100 PY; 95% 0.52, 5.01), hepatitis C (0.96 per 100 PY; 95% 0, 4.02) and any STI except HIV (21.00 per 100 PY; 95% 15.80, 30.69). In unadjusted mixed effects models, risk of incident STIs did not vary by older age, marriage, engagement in a stable romantic relationship, offering services to five or more clients, alcohol use, polysubstance use, sexual assault perpetration, condom use, provision of penetrative sex or provision of receptive sex (Table 1). However, risk of STIs did

Abstract P019–Table 1. Unadjusted associations between selected time-varying factors and incident sexually transmitted infections

| Characteristics                                      | Odds ratio | 95% confidence limits |
|-------------------------------------------------------|------------|-----------------------|
| Age greater than 24 years                             | 0.76       | 0.30, 1.90            |
| Educational attainment                                |            |                       |
| Primary or secondary school                           | Reference  | Reference             |
| High school                                           | 0.28       | 0.09, 0.85            |
| College or post-graduate school                       | 0.13       | 0.03, 0.53            |
| Married                                               | 1.34       | 0.18, 10.17           |
| Had stable romantic partner during last follow-up     | 1.06       | 0.53, 2.13            |
| Had vaginal, anal or oral sex with five or more clients last week | 0.71       | 0.40, 1.27            |
| Used alcohol while having sex with any of three most recent clients | 0.81       | 0.33, 1.99            |
| Used a substance (drugs or alcohol) while having sex with any of three most recent clients | 1.45       | 0.54, 3.88            |
| Perpetrated assault of any of three most recent clients | 0.20       | 0.03, 1.36            |
| Frequently used condoms during sex in the past month  | 0.77       | 0.30, 1.94            |
| Had penetrative anal sex with any of 3 most recent clients | 0.70       | 0.32, 1.55            |
| Had receptive anal sex with any of 3 most recent clients | 1.04       | 0.47, 2.30            |
differ by educational attainment and was lower among those who completed high school (odds ratio (OR) = 0.28, 95% 0.09, 0.85) or college/post-grade education (OR = 0.13, 95% 0.03, 0.53) compared with those who had only completed primary or secondary schooling. The association between risk of STI infection and completion of high school (adjusted OR (AOR) = 0.23; 95% 0.06, 0.93) or college/post-graduate education (AOR = 0.17; 95% 0.03, 0.93) persisted in the multivariable adjusted model.

Conclusions: Our findings suggest that HIV/STI incidence is high among MSW in Mexico City and should be a priority population for treatment and prevention interventions. Education appears to be an important potential predictor of HIV/STI infections and may be an important component of economic and structural interventions to prevent infections.

http://dx.doi.org/10.7448/IAS.19.2.21048

P020
Changes in renal laboratory parameters and bone mineral density in treatment-naïve HIV-1-positive adolescents initiating therapy with INSTI-based single-tablet regimens containing tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF)
Ellen Koenig 1; Aditya Gaur 2; Hilda Kizito 3; Wasana Prasitsuebsa 4; Natellas Rakhmanina 5; Kulkanya Chokephala 6; Jan Fourie 7; Linda-Gail Bekker 8; Yongwu Shao 9; Sean Bennett 10; Anita Silva 11 and Erin Quirk 10

Introduction: The comparative safety data through 24 weeks are reported.

Materials and methods: Exposures of all components have been shown to be within the range associated with antiviral activity in adults. Preliminary comparative safety data through 24 weeks are reported.

Results: The E/C/F/TAF and STB trials enrolled 50 and 33 adolescents, respectively (median age 12 vs. 16 years, 56% vs. 30% female, 88% vs. 76% black, 22% vs. 27% with baseline HIV-1 RNA > 100,000 copies/mL, med CD4 count 456 vs. 407 cells/µL, median eGFR 156 vs. 143 mL/min/1.73 m²). Most AEs in both trials were mild and unrelated to treatment, with no deaths or AEs leading to treatment discontinuation. At week 24, the median increase in serum creatinine was +0.08 mg/dL in E/C/F/TAF participants and +0.10 mg/dL in STB participants, with median eGFR decreases of −17.0 and −18.0 mL/min/1.73 m², respectively, consistent with COBI's inhibition of renal tubular creatinine secretion. Proteinuria (any grade) occurred in 26% of E/C/F/TAF participants versus 52% of STB participants, with Grade 2 or higher proteinuria occurring in 4% versus 21% of participants, respectively. Of those participants with BMD measurements at week 24, the median increase in spine BMD was +1.98% in E/C/F/TAF participants, with a decrease of ≥4% in 3/41 participants (7%), versus a median decrease of −1.29% in the STB cohort, with a decrease of ≥4% in 6/20 participants (30%). Spine HZ scores decreased by −0.02 and −0.21, respectively.

Conclusions: Compared with STB, E/C/F/TAF exhibited similar effects on eGFR, a lower incidence and severity of proteinuria, and a median increase in spine mineralization. Both STRs were well-tolerated through 24 weeks. These findings support INSTI-based STRs as initial HIV-1 treatment in adolescents and suggest that TAF could offer safety advantages in paediatric populations.

http://dx.doi.org/10.7448/IAS.19.2.21049

P021
Salud a la Vida: developing HIV and hepatitis C prevention through community collaboration between a Hispanic-serving institution and its surrounding community
Britt Rios-Ellis 1; Mara Bird 2; Melawhy Garcia-Vega 3; Miguel Angel Ortiz Valenzuela 4; Dilia Ortega 5 and Luis Cendejas 6

Introduction: HIV and hepatitis C (HCV) represent two of the greatest viral health challenges facing Latinos in the United States. While comprising 17% of the U.S. population, Hispanics account for 21% of HIV diagnoses (CDC, 2016). Furthermore, HCV rates among Latinos rose to 21.4% in 2011 (CDC, 2016). Another alarming trend can be observed in the age of HIV diagnosis with 24% of new infections seen in Latinos aged 13 to 24 compared with only 16% of whites (CDC, 2012).

Materials and methods: As access to higher education increases for Latinos, Hispanic Serving Institutions (HSIs), in particular, provide a welcome venue to conduct HIV and HCV screening and prevention education. Furthermore, because HSIs are more likely to be populated with commuter students and more often located in regions wherein Latinos comprise a substantive portion of the population, the opportunity to create community-campus prevention partnerships has broad potential for substantive education. To optimize this possibility, the U.S. Department of Health and Human Studies Substance Abuse and Mental Health Services Administration (SAMHSA) initiated a community-campus programme development initiative linking HIV and HCV. Salud a la Vida was developed to create a lasting University-Community Based Organization partnership designed to build capacity on the California State University Long Beach (CSULB) campus and within the Long Beach community to deliver effective, integrated HIV and hepatitis C prevention programmes. Salud a la Vida was developed to create a lasting University-Community Based Organization partnership designed to build capacity on the California State University Long Beach (CSULB) campus and within the Long Beach community to deliver effective, integrated HIV and hepatitis C prevention programmes. Salud a la Vida was developed to create a lasting University-Community Based Organization partnership designed to build capacity on the California State University Long Beach (CSULB) campus and within the Long Beach community to deliver effective, integrated HIV and hepatitis C prevention programmes.
assess HIV and HCV knowledge, attitudes, testing history, community needs and risk. Transcript analysis revealed basic HIV prevention knowledge but a general inability to distinguish HCV and HIV. Furthermore, baseline HCV knowledge was extremely low and youth had little to no previous knowledge regarding screening or risk. Alcohol and marijuana use was common, and 93% of participants had not used a condom at last sexual intercourse.

Conclusions: Focus group results in collaboration with peer community health worker recommendations were used to establish the Salud a la Vida HIV/HCV outreach education programme. Focus group findings and preliminary programme results will be presented.

References
1. Latinos and HIV/AIDS (April 2014). The Henry J. Kaiser Family Foundation. https://kaiserfamilyfoundation.files.wordpress.com/2014/04/6007-11-latinos-and-hiv-aids1.pdf
2. Centers for Disease Control and Prevention. HIV Surveillance Supplemental Report, Vol. 17, No. 4. Centers for Disease Control and Prevention; 2012.
3. Centers for Disease Control and Prevention. March, 2014. Hispanics/ Latinos. http://www.cdc.gov/tb/publications/PDF/TBHispanics.pdf

P022
Late diagnosis and adherence problems as determinants of AIDS mortality in Argentina: profile of people who died from AIDS in the Metropolitan area of Buenos Aires in 2010
Adriana Durán1; Eduardo Perez2; Ariel Adaszko3; Valeria Levite4; Sebastián Nardi5; Marcelo Vila6; Clarisa Brezzo7; Carlos Guevel8 and Mercedes Fernández9
1HIV/AIDS and STD Program, Ministry of Health, Buenos Aires, Argentina. 2PHO, WHO, Buenos Aires, Argentina. 3UNAIDS, UNAIDS, Buenos Aires, Argentina. 4Health Statistic and Information Program, Ministry of Health, Buenos Aires, Argentina.

Introduction: The early diagnosis of HIV as well as the access to the highly active antiretroviral therapy (HAART) of people living with HIV is key to avoid AIDS mortality. In our country, in spite of the fact that HAART is available for free, and active policies to promote testing have been implemented, 1400 people die from AIDS every year. It is essential to know the characteristics of people who die due to causes related to AIDS in order to define strategic interventions in the most vulnerable groups.

Materials and methods: A retrospective observational study was carried out among people over 18 years old who died from a basic cause related to AIDS during 2010 in the Metropolitan Area of Buenos Aires. A collection tool was used to gather information about medical records of hospitalized people and outpatients. Absolute and relative frequency rates were obtained and tests of statistical significance in the analyzed variables were calculated whenever appropriate.

Results: A total of 331 deaths were studied, out of which 64% took place in the Autonomous City of Buenos Aires. The average age of the people studied was 40 years and 64% were men; 71.3% lived in areas that belong to the province of Buenos Aires. The main mode of transmission was unprotected opposite-sex sexual intercourse, both in men and women. 31% of the deaths were of people who had a late diagnosis, and 40% of them were diagnosed while in the same hospital in which death occurred. The median period of time since the diagnosis and death was of five years, and it was shorter in men than in women (p < 0.05). The main causes of deaths in confirmed diagnoses were tuberculosis, both pulmonary and disseminated, and meningeal cryptococcosis. The presence of a great number of defining diseases and the clinical and immune deterioration was a common result in all the hospitalizations that were analyzed.

The prevalence of hepatitis B and C infections was of 28.4% and 39.4%, respectively.

Conclusions: A high percentage of people who died from AIDS in The Metropolitan Area of Buenos Aires during 2010 had been late diagnosed, which appears to be one of the main characteristics of the deaths. The studied population had irregular contact with the health system, as to receive an early diagnosis as well as a proper outpatient’s treatment.

http://dx.doi.org/10.7448/IAS.19.2.21050

P023
Prevalence of HIV infection among imprisoned women in Brazil: a cross-sectional survey in the State Prison System of São Paulo
Tânia Regina Correa Souza1; Alberto Novaes Ramos Jr3; Wedja de Almeida Sparingier1; Márcia Teresinha F Santos2; Maria Aparecida Silva2; Anna Luiza Placco1; Samantha Moreira Lamastro1; Solange Medeiros Pongelupi1; Carmen Silva B Domingues2 and Maria Clara Gianna2
1São Paulo State Program for STDs and AIDS, STD and AIDS Referral and Training Center, São Paulo State Department of Health, São Paulo, Brazil. 2School of Medicine, Federal University of Ceara, Department of Community Health, Fortaleza, Brazil. 3Health Coordination of the Prison System, São Paulo State Department of Penitentiary, São Paulo, Brazil.

Introduction: The increase of 78.3% of the female prison population in Brazil in the period 2005 to 2013 has brought great challenges, especially those related to the vulnerability to sexually transmitted infections [1]. Gender inequality, stigma and discrimination increase imprisoned women’s vulnerability to HIV infection [1,2]. The State of São Paulo (SSP) accounts for 30% of this Brazilian population and has sought to develop actions within the National Policy for Integral Women’s Health [3]. The aim of this study was to estimate the prevalence of HIV infection in women deprived of freedom in SSP, to establish parameters for monitoring and evaluation.

Materials and methods: Cross-sectional seroepidemiological survey for HIV infection was conducted in 19 female prisons of SSP. This study was coordinated by the State Program of STD/AIDS in São Paulo and conducted from August 2012 to December 2013. The estimated population basis was 11,530 women in all prison units. The stages of the study include counselling, information about the intervention, guidance on the sexually transmitted diseases, free and informed consent to data collection and the offer of testing for HIV and syphilis. For the definition of HIV infection status, we used rapid diagnostic tests. Data analysis was based on the estimated prevalence with calculation of confidence intervals.

Results: Of the total 8821 (76.5%) addressed women, 8740 (99.1%) underwent rapid diagnosis for HIV testing. The estimated prevalence of HIV infection from this evaluation was 2.84% (95% confidence interval [CI]: 2.46% to 3.16%), 248 infected women. HIV infection by prison unit in São Paulo varied from 0% (CRF and CRF Araraquara Rio Claro) to 10.20% (PF Capital – 95% CI: 7.64% to 12.76%). The integrated analysis identified co-infection (HIV and Treponema pallidum) in 36 women, estimated prevalence of 0.47% (95% CI: 0.33% to 0.61%).

Conclusions: This is the first study-based action in this extension in SSP. This population-based survey reinforces the status of great vulnerability to HIV infection for women in the State penal system, both in urban and rural realities. This study brings as possibilities to be assigned: establishment of flowcharts and indicators for monitoring and evaluation of preventive and therapeutic strategies to this population, establishment of appropriate flowcharts to the State Epidemiological Surveillance System, definition of elements for
interventions in the prison system addressing public health policies and scientific knowledge production from this and other nested publications to the project [3,4]. These initiatives could ultimately contribute to improving the quality of life of women with a neglected and vulnerable condition [2,3,4].

References
1. Matida LH (Organizadora); Ramos NA Jr AN, Placco AL, Santos MTF, Silva MA, Lattari MCT, et al. O HIV e a Sífilis no Sistema Prisional Feminino do Estado de São Paulo. São Paulo, Secretaria de Estado da Saúde, 2015.v 64 pgs. http://www.unodc.org/documents/lpo-brazil/noticias/2013/09/hiv_e_sifilis_no_sistema_prisional_feminino1.pdf
2. Brasil. Política Nacional Integral à Saúde da Mulher – princípios e diretrizes; 2007. 209 pp. http://conselho.saude.gov.br/ultimas_noticias/2007/politica_mulher.pdf
3. São Paulo. Secretaria da Administração Penitenciária do Estado de São Paulo. Coordenadoria de Reintegracao Social e Cidadania. Departamento Penitenciário Nacional do Ministério da Justiça. Manual de Diretrizes de Atenção à Mulher Presa, São Paulo, 2013. http://www.reintegracaoocial.sp.gov.br/db/crsc-kyu/archives/6208c81b200c6081c054d541387c7b.pdf
4. São Paulo. Centro de Referência e Treinamento em DST/AIDS. Planos Estratégicos – Programa Estadual DST/AIDS/SP. São Paulo, 2012. http://www.saude.sp.gov.br/resources/crt/publicacoes/publicacoes-crt/plano2012.pdf

http://dx.doi.org/10.7448/IAS.19.2.21052

P024
HIV cascade of care and viral load suppression in trans-men and women who have sex with men populations in the Dominican Republic
Robert Paulino1; Mayara Rodriguez-Lauzurique2; Ricardo Domingo1; Leandro Tapia1; Paola Peña3 and Jose A Duran3
1Universidade Iberoamericana, Research Department, School of Medicine, Santo Domingo, Dominican Republic. 2Centro de Orientacion e Investigacion Integral-COIN, Psychology, Santo Domingo, Dominican Republic. 3Universidad Iberoamericana, School of Medicine, Santo Domingo, Dominican Republic.

Introduction: The overall rate of new HIV infections appears to be in decline worldwide; however, among key populations, men who have sex with men (MSM) and trans-women (TGW), new HIV infections continue growing [1]. Since the introduction of highly active anti-retroviral therapy (HAART), people living with HIV live longer than ever before. The HIV cascade of care is a comprehensive monitoring tool to evaluate the HIV continuum of care and to evaluate “leakage points” along the points of attention [2]. The objective of this study was to evaluate the HIV cascade along the services in MSM and TGW and compare this with the general HIV population in an outpatient clinic in Santo Domingo, Dominican Republic.

Materials and methods: We used a retrospective database of one outpatient clinic for HIV patients to assess our population-based cascade. Paper-based data were collected from clinical files. Characterization of target populations was based on past clinical history or self-identification as exclusively MSM or TGW and compared with the HIV-positive with unknown risk (+WUR). Treatment access and administration of HIV drugs was based according with the Dominican Republic Ministry of Health criteria (< 350 cell/µL) and viral suppression below 20 copies/mL.

Results: We identified 405 HIV diagnosed individuals during the study period; 60% were male. Of these, 25.18% (n = 102) were MSM and TGW. Overall, 64.44% in the +WUR was retained in care versus 65.68% in MSM/TGW (Figure 1). HAART access in +WUR was 56.04%, while in MSM/TGW 38.29%. Viral suppression in +WUR was 43.70% and in MSM/TGW 24.50%.

Conclusions: We found a significant difference between access to HAART and viral suppression in both groups. It is necessary to note that higher viral loads among these groups will be of significant influence for HIV persistence in social and sexual networks. Drops in the proportion to be achieved in each step may be a reflection of challenges specific to MSM/TGW access to care. It is necessary to evaluate the potential role of antiretroviral and hormone replacement therapy interactions.

References
1. PEPFAR (2012). Blueprint for Creating an AIDS-Free Generation. Available: http://www.pepfar.gov/documents/organization/201386.pdf
2. Hogg L, Lima V, Sterne JA, Grabar S, Battegay M, Bonarek M, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293–9.

http://dx.doi.org/10.7448/IAS.19.2.21053

P025
Dyslipidaemia in transgender women before and after cross-sex hormone treatment and ART
Esmeralda Román1; Armando Sánchez1; Edgardo Hamid Vega2; Jeremy B Cruz2; Andrea Gonzalez Rodríguez3 and Pablo Belaunzaran Zamudio4
1Clínica Especializada Condesa, Clínica Trans, Mexico City, Mexico. 2Clínica Especializada Condesa, Salud Mental, Mexico City, Mexico. 3Clínica Especializada Condesa, Salud Mental, Mexico City, Mexico. 4UNAM, División de Investigación, FM, Mexico City, Mexico.

Introduction: Transgender women (TGW) are a key population in the HIV epidemic. Most of these women use hormones, which may lead to a higher cardiovascular risk. It is unknown whether the use of hormonal therapy (HT) in combination with antiretroviral drugs (ARTs) potentiate even greater changes in lipids. In this study, we describe the prevalence and cumulative incidence of dyslipidaemia in TGW receiving HT, ARTs or both at Clínica Condesa in Mexico City.

Methods: This is an observational cohort study. We retrieve data on total cholesterol (TC), triglycerides (TG), high-density cholesterol (HDL) and low-density cholesterol (LDL) of TGW receiving care at Clínica Condesa (CC), at baseline and the last available measurement.

Results: We included 697 TGW receiving care in the Transgender Clinic of CC between January 2009 and January 2016 with available baseline lipid profile (60% of all TGW receiving care); 236 (33%) were...
HIV positive. At baseline, 38 (5.5%) had hypercholesterolaemia (< 239 mg/dL; six (2.5%) HIV positive and 32 (7%) HIV negative (p = 0.02); 142 (20%) had hypertriglyceridaemia (< 200 mg/dL; 92 (39%) HIV positive and 50 (11%) HIV negative (p < 0.001). Also, 265 (38%) had low-HDL levels (< 40 mg/dL; 114 (48%) HIV positive and 151 (33%) HIV negative (p = 0.008); and 34 (4.9%) had high-LDL (> 160 mg/dL; 4 (1.7%) HIV positive and 30 (6%) HIV negative (p = 0.007). There were 341 (49%) subjects with follow-up lipid profile measurements at their last visit, of whom 83 (24%) were HIV positive; 236 of 258 HIV-negative TGW (91%) were receiving HT. Among HIV-negative TGW, 13 (5%) had hypercholesterolaemia, 51 (20%) hypertriglyceridaemia, 89 (34%) low-HDL cholesterol and 12 (5%) high-LDL. Eighty (96%) HIV-positive subjects were receiving ART and 73 (88%) HT. Four (5%) HIV-positive TGW presented hypercholesterolaemia during follow-up, 22 (26%) hypertriglyceridaemia, 34 (41%) low-HDL and 2 (2.4%) high-LDL. The proportion of TGW with hypertriglyceridaemia was not different by HT group.

Conclusions: The most common dyslipidaemia in TGW receiving care at CC before and during HT and ART were low levels of HDL followed by hypertriglyceridaemia. HIV-infected TGW had a higher baseline prevalence of hypertriglyceridaemia and low HDL. The proportion of patients with hypertriglyceridaemia and low HDL increased in HIV-negative TGW during follow-up and decreased in HIV-infected TGW, possibly due to the timely intervention with dietary treatment and effect of ART. There was no increase in lipid abnormalities in patients using HT, ART or both.

http://dx.doi.org/10.7448/IAS.19.2.21054

P026
Prevalence of elevated depression symptoms and key associated factors among female sex workers and women living with HIV in the Dominican Republic
Christine Rael and Alissa Davis
Columbia University, HIV Center for Clinical and Behavioral Studies, New York, USA.

Introduction: Little is known about the mental health of female sex workers (FSW) and women living with HIV (WLWH) in the Dominican Republic (DR), which may impede the effectiveness of HIV prevention, testing and treatment programming. This is important, since studies across multiple sociocultural contexts show that the prevalence of depression in FSW ranges from 50% to 80%. Depression is also prevalent in WLWH, ranging from 25.8% to 81.0%. There is almost no scientific work about depression in FSW and WLWH in the DR. This is problematic, since the DR is home to a generalized HIV epidemic (0.8% to 1.5%) and a concentrated HIV epidemic for FSW (3.3% to 8.4%), making this a high priority area for study.

Materials and methods: This study estimated the prevalence of elevated depression symptoms and identified key correlates in FSW, WLWH and a comparison group. Participants were FSW (N = 349), WLWH (N = 213) and a comparison group of HIV-negative women who were not sex workers (N = 314) from San Felipe de Puerto Plata, DR. Participants completed questionnaires assessing demographics and depression. FSW and WLWH completed items ascertaining HIV or sex work-related internalized stigma. Descriptive statistics summarized the demographic characteristics of the sample, and chi-square (categorical variables) and t-tests (continuous variables) detected significant differences between the comparison group and FSW or WLWH. Unadjusted and adjusted logistic regressions identified significant relationships between covariates and the outcome variable, elevated depression symptoms (EDS). Interaction terms were calculated to test the strength of association of significant relationships with (1) FSW and the comparison group and (2) WLWH and the comparison group.

Results: EDS were prevalent across all three populations under study: FSW (70.2%), WLWH (81.1%) and the comparison group (52.2%). Internalized stigma increased the odds of EDS for FSW (AOR = 2.73; 95% CI = 1.95 to 3.84) and WLWH (AOR = 3.06; 95% CI = 1.86 to 5.05). Higher permanent income lowered the odds of this outcome for FSW (AOR = 0.88; 95% CI = 0.70 to 1.09) and comparison group women (AOR = 0.94; 95% CI = 0.86 to 1.01). Interaction terms revealed that being a member of the FSW or WLWH group did not strengthen or weaken the relationships between covariates and EDS.

Conclusions: The high prevalence of EDS across all three groups suggests that interventions to treat depression and its causes could benefit all women, regardless of HIV status or HIV risk. Interventions focused on addressing internalized stigma for FSW and WLWH could be particularly effective in reducing EDS in these two groups. Additionally, future depression-related interventions in the DR should address poverty, since this appears to play an important role in mental health.

http://dx.doi.org/10.7448/IAS.19.2.21055

P027
Trends of the HIV/AIDS epidemic in men who have sex with men in the state of São Paulo, Brazil
Mariza Vono Tancredi1; Carmen Silvia B Domingues1; Angela Tayra2; Marcia Cristina Polon1 and Maria Clara Gianna4
1CRT DST/AIDS - SP, Epidemiology, São Paulo, Brazil. 2CRT DST/AIDS - SP, Director, São Paulo, Brazil.

Introduction: Trends study allows us to perform future projections and anticipate results on the HIV/AIDS epidemic trends. The objectives were to describe and analyze the AIDS and the HIV-positive cases trends in the state of São Paulo, in teenagers and adults, during the period of 2004 to 2013, according to age groups and men who have sex with men (MSM).

Materials and methods: Trends study was performed with AIDS and HIV-positive notification data compared by age group and exposure categories. It was considered as a dependent variable (Y), the annual number of HIV-positive patients and the number of AIDS cases, growing trends were observed only in the age group of 13 to 19 years. The most common dyslipidaemia in TGW receiving care at CC before and during HT and ART were low levels of HDL followed by hypertriglyceridaemia. HIV-infected TGW had a higher baseline prevalence of hypertriglyceridaemia and low HDL. The proportion of patients with hypertriglyceridaemia and low HDL increased in HIV-negative TGW during follow-up and decreased in HIV-infected TGW, possibly due to the timely intervention with dietary treatment and effect of ART. There was no increase in lipid abnormalities in patients using HT, ART or both.

http://dx.doi.org/10.7448/IAS.19.2.21054
MODELS OF CARE/SCALE UP OF TREATMENT

P028
Patient-centred HIV care in Mexico City: basis for a primary care model and its potential impact on the cascade of care
Jesus Casillas Rodriguez1, Diana Molina-Martinez1 and Andrea Gonzalez Rodı´guez2
1Clinica Condesa, Internal Medicine, Mexico City, Mexico. 2Mexico City HIV Program, Executive Direction, Mexico City, Mexico.

Introduction: Mexico has a concentrated epidemic with an estimated 180,000 HIV-positive individuals in 2014, which translates to a prevalence of 0.3%. Among Mexico’s 32 states, Mexico City has consistently had the highest cumulative HIV-AIDS incidence, being the oldest epidemic so far. Considering HIV a chronic disease, public health strategies should be implemented to optimize medical care programmes in ambulatory settings.

Materials and methods: Condesa Clinic is Mexico City’s ambulatory HIV unit that assists more than 10,000 active patients up to January 2016. We describe a new medical protocol to detect, evaluate and incorporate new HIV patients to the clinic. This protocol has been implemented since 2012 and is updated yearly according to results. We started an early incorporation to medical assistance and a time reduction strategy to start HAART, which potentially will reduce the number of lost patients (Figure 1).

Results: As of January 2016, 10,459 patients are assisted in Condesa Clinic, 95.5% on treatment (n = 9,990) and 4.48% (n = 469) on follow-up. With more than 2000 new HIV-positive diagnosed every year from 2013 to 2015, we evaluated the effects of implementing the new strategy on retention and therapy rate. From 2208 new HIV detections in 2013, 30.1% patients were lost (30.1%, 666), half of them before medical evaluation. There were 1839 medical evaluations and incorporation to medical assistance (57.3%) and 841 initiated HAART in the following week (79.7%); 478 patients were referred to other centres (25.9%). The strategy also includes 8-week viral load to detect early virological failures. With this strategy, the comparative time to undetectability in those starting HAART was reduced from 12.9 (2009) to 5.9 months (2015). Of those on treatment, 99.7% have had a viral load/CD4 determination in the last year, and those with more than 6 months of therapy (n = 9,056), 89.2% (8,079) and 98.6% had viral load of <50 and <200 copies/mL, respectively.

Conclusions: The new HIV Care algorithm implemented allows to detect, evaluate and retain more patients, reducing the time to undetectability and the potential of HIV transmission. This is the first approach to early incorporation of HIV patients into medical care and early therapy starting time.

http://dx.doi.org/10.7448/IAS.19.2.21057

P029
Assessing mental health among recently diagnosed HIV patients at Condesa Clinic in Mexico City
E Hamid Vega-Ramirez1, Victor Rodriguez1, Jeremy B Cruz2, Valeria Daniela Ferreya3, Carolina Rocabert1, Harumi Hirata1 and Andrea Gonzalez Rodı ´guez2
1Mental Health Programme, Condesa Specialized Clinic, Mexico City, Mexico. 2Condesa Specialized Clinic, Mexico City, Mexico.

Introduction: Several factors, such as psychosocial and uncontrolled HIV infection in the central nervous system, contribute to the onset of a mental disorder. Common mental disorders are more prevalent in people with HIV (i.e. depressive disorders, cognitive impairment and substance use disorders) [1]. The aim of this study is to describe the mental healthcare process and some preliminary results of recently diagnosed HIV patients at the Condesa Clinic that have been assessed by the Mental Health Programme (MHP).

Materials and methods: We describe the model of care of the MHP incorporated into the HIV treatment cascade at the Condesa Clinic for recently diagnosed patients (Figure 1). We used univariate analysis for preliminary data.

Abstract P028 - Figure 1. Integrated Care Model to detect, evaluate, treat and retain new HIV patients in Mexico City.
Results: On 2012, the MHP was created. Based on the international evidence [2] and the needs of the Condesa Clinic patients, the MHP developed a process that included early detection and treatment for mental disorders. Within the first week of initial medical assessment, patients recently diagnosed with HIV had an evaluation to detect any mental disorder that could impair adherence to HAART or impact patients’ quality of life. A clinical psychologist through a clinical interview based on DSM-5/ICD-10 criteria and valid psychometric instruments [3] performs this evaluation. If the patient had an adjustment disorder, he/she received a brief intervention. If the patient had a moderate or severe common mental disorder, he/she received psychopharmacological treatment by a psychiatrist; and if the patient had acute psychosis or suicidal ideation, he/she was referred to a psychiatric hospital. MHP has evaluated 2158 patients, most of whom were men (89.0%), middle aged (30.9 ± 9.3), with 11.8 (± 3.9) years of formal education and single (76.7%). The 37.9% did not have any mental disorder at the moment of the mental assessment, but 35.3% had an adjustment disorder, 8.8% a depressive disorder, 4.3% an alcohol use disorder, 2.7% an anxiety disorder and 11.0% other disorders. They also had a mean viral load of 293,922 (± 903,286) copies/mL, and a mean CD4 count of 308 (± 229) cell/μL.

Conclusions: Incorporation of mental healthcare services to the HIV treatment cascade at first-level facilities could be feasible and probably effective in order to help retention, to adhere to HAART and to get undetectable viral loads in patients. Further analysis to detect mental health factors related to unfavourable outcomes in HIV patients should be performed.

References
1. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.
2. Sherr L, Clucas C, Harding R, Sibley E, Catalan J. HIV and depression – a systematic review of interventions. Psychol Health Med. 2011;16(S):493–527.
3. Ramasubbu R, Taylor VH, Samaan Z, Sockalingham S, Li M, Patten S, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry. 2012;24(1):91–109.

http://dx.doi.org/10.7448/IAS.19.2.21058

P030
High rate of linkage to care and antiretroviral therapy initiation in Haiti and improvements over time
Nancy Dorvil1; Kelly Hennessey2; Colette Guiteau3; Vanessa Rivera4; Jessy Devieux5; Margaret McNair6; Patrice Severe7; Adias Marcelin8; Pierrot Julma9; Sidney Atwood10; Serena Koenig8 and Jean William Pape8
1Les Centres Gheskio, Clinical Trials Unit, Port-au-Prince, Haiti. 2Clinical Research, Analysis Group, Boston, MA, USA. 3Les Centres Gheskio, Adult ARV Clinic, Port-au-Prince, Haiti. 4Weill Cornell Medical College, Center for Global Health, New York, USA. 5AIDS Prevention Program, Florida International University, Miami, FL, USA. 6Les Centres Gheskio, Data Management, Port-au-Prince, Haiti. 7Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA. 8Les Centres Gheskio, Port-au-Prince, Haiti.

Introduction: High attrition during the period from HIV testing to antiretroviral therapy (ART) initiation is widely reported. Though treatment guidelines have changed to broaden ART eligibility and services have been widely expanded over the past decade, data on the temporal trends in ART initiation rates are limited. Materials and methods: We evaluated temporal trends and predictors of retention for each step from HIV testing to ART initiation over the past decade at the Gheskio clinic in Port-au-Prince Haiti. The 22,638 patients >17 years of age who received a positive HIV test at Gheskio from 1 March 2005 to 28 February 2015 were included. Patients were followed to determine if they received all steps for ART staging and initiated ART within 6 months after HIV testing. Results: A total of 22,638 patients (60% female, median age 35 years) were included. 15,756 patients (70%) had blood drawn for CD4 count – this increased from 31% in 2005 to 82% in 2014 (p < 0.0001). The time from HIV test to blood draw decreased over time, from a median of 79 days (IQR: 30 to 182) in 2005 to 0 days
A total of 14,482 patients (92%) returned for CD4 count results; this increased from 93% in 2005 to 96% in 2014 ($p < 0.61$). The time from blood draw to return for CD4 count result decreased over time, from a median of 8 days (IQR: 3 to 15) in 2005 to 6 days (IQR: 2 to 14) in 2014 ($p = 0.04$). A total of 5,885 patients who were eligible for ART at presentation initiated treatment; this increased from 24% in 2005 to 95% in 2014 ($p < 0.001$). The median time from return for CD4 count result to ART initiation decreased from 3 days (IQR: 0 to 19) in 2005 to 0 days (IQR: 0 to 0) in 2014 ($p < 0.001$) (see Figure 1 for a bar chart of retention at different time points). Predictors of ART initiation included later year of HIV testing, older age and higher educational status.

Conclusions: The proportion of patients newly diagnosed with HIV who initiate ART has increased over the last decade in Haiti. Over the same time period, services have been delivered more rapidly. ART is now provided to most patients on the day that CD4 count results are provided, with very high rates of treatment initiation.

http://dx.doi.org/10.7448/IAS.19.2.21059

### Median CD4 count increase at ART initiation in Ministry of Health of Mexico between 2010 and 2015

Marisol Valenzuela-Lara; Carlos Magis Rodríguez; Eduardo Becerril-Vargas and Eddie Antonio León Juárez
CENSIDA, DAI, Mexico City, Mexico.

**Introduction**: The global scale-up of antiretroviral therapy (ART) over the past decade represents one of the great public health and human rights achievements of recent times. Both the standardization and simplification of prescribing practices have been critical to ART scale-up. Actually, an antiretroviral regimen for a treatment-naïve patient generally consists of two nucleoside reverse transcriptase inhibitors in combination with a third active antiretroviral drug. These guidelines are supported by studies of effectiveness, durability, optimal tolerance and comfort.

**Materials and methods**: The objective of this study was to assess trends in the median CD4 count, number of people living with HIV initiating ART and the proportion of people in each regimen according to the third ARV, between 2010 and 2015 in Mexico Ministry of Health (MoH). We examined transversal data from 63,970 adults (aged ≥15 years) who initiated HIV treatment programmes at 138 HIV care clinics in Mexico between 2010 and 2015. The clinics included are part of Mexico MoH. Patient information is routinely collected in the “Antiretroviral Management, Logistic and Surveillance System” (SALVAR in Spanish). We defined CD4 count “at ART initiation” as any measurement three months before or one month after ART initiation. Statistical analyses were carried out using STATA, version 11.1.

**Results**: Between 2010 and 2015, the median ART initiation age was 33 years. The median CD4 count at ART initiation increased from 183 to 242 cells/µL, k-sample test on the equality of medians was performed, $p < 0.0001$, and an increase of 9.8 cell/year was observed; sex disparities were reduced from a male–female difference of 52 cells in 2010 to 13 cells in 2015 (Figure 1). The
number of persons initiating ART each month has increased from 720 in 2010 to 1,174 in 2015, year with the highest annual changes observed in the last five years (Figure 2), (Table 1). In 2010, 52.9% of ART initiation schemes had efavirenz, in 2015 this figure was 80.1%.

Conclusions: Guidelines in Mexico have been in change, especially in the last couple of years, and the impact of this change is observed in the increase of CD4 at ART initiation. According to national guidelines, efavirenz has been the preferred third ARV, and the increase in the use of this ARV shows a more standardized prescription. Still intensified efforts are needed to initiate ART more opportunely.

http://dx.doi.org/10.7448/IAS.19.2.21060

P032
Early diagnosis and continuity of care of people with HIV in Argentina: gaps to achieve the 90-90-90 goals
Adriana Durán1; Eduardo Perez2; Ariel Adaszko3; Marcelo Vila4; Clarisa Brezzo5; Carlos Falistocco5; Sebastián Nardi5; Vanesa Kaynar5; Marysol Orlando5 and Andrea Ayma5

Introduction: The strategies implemented in response to the HIV epidemic in Argentina have impacted positively on the incidence of new cases and on AIDS mortality. However, it is estimated that 30% of people are undiagnosed and coverage of antiretroviral therapy (ART) reaches only 60%. These data demonstrate gaps with the national goals. To analyze these gaps, the Office of AIDS of the Ministry of Health, with support from UNAIDS and PAHO, developed a study to assess the conditions of linkage and retention in care and the effectiveness of ART regimens in newly diagnosed people or in naïve patients.

Materials and methods: In 2014, a concurrent cohort study was conducted with a convenience sample that was based on the jurisdictional distribution of new diagnoses of 2010. The data for each patient were gathered at the beginning of the study and 12 months later. For this work, the inclusion criterion was having had a new diagnosis in 2014.

Results: At the time of submission of this abstract, 80% of the sample had been monitored (549 of the 682 patients); 471 (86%) were included as recently diagnosed and 78 (14%) as naïve patients. Nearly 72% of the patients with recent diagnosis were still on treatment one year after the follow-up in the same health care facility. Of the remaining 28%, 51% were lost to follow-up, 33% had changed facilities and 16% were deceased. Excluding deaths and considering that referrals to other centres are not lost to follow-up, it can be concluded that after a year, 82% of patients were still monitored. The overall percentage of deaths was 4.7%; 22 of the 26 deaths occurred within a year of diagnosis. In 14 cases, the cause of death was related to an HIV-AIDS event. Treatment was indicated to 434 patients but only 409 (94%) actually started it, 308 (71%) sustained it one year later and only 54% achieved undetectable viral load values within the year. High viral load was associated with difficulties in adherence (45%), resistance development (17%) and toxicity (4%). Only 70% regularly visited the pharmacy for medication.

Conclusions: These results show that while over 90% of people diagnosed with HIV effectively initiated ART, the gap increases when assessing the sustainability and effectiveness of treatment after one year of follow-up. To achieve the universal access goals, problems linked to adherence should be addressed.

http://dx.doi.org/10.7448/IAS.19.2.21061

P033
Care model for HIV-positive pregnant women
Teresita de Jesús Cabrera López1; Ubaldo Ramos Alamillo2; Elena Langarica Naves5; Florentino Badial Hernandez2;
### Abstract 033–Table 1. Care model for HIV pregnant women

| Variable                              | Without prior HIV diagnosis (N = 38) | With prior HIV diagnosis (N = 17) | Vertical transmission of HIV (N = 4) |
|---------------------------------------|-------------------------------------|----------------------------------|-------------------------------------|
| **Socio-demographic characteristics** |                                     |                                  |                                     |
| Age (average)                         | 24.1 years                          | 25.4 years                       | 19 years                            |
| Education                             | %                                   | %                                | %                                   |
| Illiteracy                            | (5) 13.1                            | (0) 0                            | (0) 0                               |
| Primary                               | (12) 31.5                           | (3) 17.6                         | (0) 0                               |
| Secondary                             | (14) 38.8                           | (7) 41.1                         | (2) 50                              |
| High school                           | (4) 10.5                            | (5) 29.4                         | (2) 50                              |
| University                            | (3) 7.8                             | (2) 11.7                         | (0) 0                               |
| Occupation                            | %                                   | %                                | %                                   |
| Housewife                             | (26) 68.4                           | (11) 64.7                        | (3) 75                              |
| Employed                              | (9) 23.6                            | (4) 23.4                         | (0) 0                               |
| Other                                 | (2) 5.2                             | (2) 11.7                         | (0) 0                               |
| Student                               | (1) 2.6                             | (0) 0                            | (1) 25                              |
| Marital status                        | %                                   | %                                | %                                   |
| Common marriage                       | (29) 76.3                           | (9) 52.9                         | (2) 50                              |
| Single                                | (8) 21                              | (6) 35.2                         | (1) 25                              |
| Married                               | (1) 2.6                             | (2) 11.7                         | (1) 25                              |
| Partner                               | %                                   | %                                | %                                   |
| Serodiscordant                        | (12) 31.5                           | (9) 52.9                         | (4) 100                             |
| Concordant                            | (21) 55.2                           | (2) 11.7                         | (0) 0                               |
| Unknown                               | (5) 13.1                            | (6) 35.2                         | (0) 0                               |
| Drug use                              | %                                   | %                                | %                                   |
| Yes, during pregnancy                 | (4) 10.5                            | (1) 5.8                          | (0) 0                               |
| **Characteristics of HIV infection**  |                                     |                                  |                                     |
| Initial viral load                    | Median 10,490 c/mL (SD 141,677)     | 52.9% detectable                 | 100% detectable                     |
| Initial CD4 (c/μL)                    | Median 336 c/μL (SD 189.5)          | Median 366 c/μL (SD 277.7)       | Median 316 c/μL (SD 99.9)           |
| HAART                                 | %                                   | %                                | %                                   |
| RAL+TDF/FTC                           | (16) 42.1                           | (3) 17.6                         | (0) 0                               |
| ATV+R+TDF/FTC                         | (12) 31.5                           | (6) 35.2                         | (0) 0                               |
| LPV/R+3TC/AZT                         | (8) 21                              | (2) 11.7                         | (2) 50                              |
| TDF/FTC/EFV                           | (0) 0                               | (4) 23.5                         | (0) 0                               |
| LPV/R+TDF/FTC                         | (2) 5.2                             | (2) 11.7                         | (2) 50                              |
| Weeks on HAART after HIV diagnosis    | Median 9 weeks (SD 8.1)             | Median 18 weeks (SD 9.7)         | Median 24 weeks (SD 6.7)            |
| Final VL c/mL                         | 73.6% undetectable (n = 28), 26.3% detectable (n = 10), median 429 (D.E. 10,361) | 64.7% undetectable (n = 11), 35.2% detectable (n = 6), median 124.5 (D.E.189) | 75% (n = 3) undetectable, 25% detectable (57 c/mL) |
| Final CD4 c/μL                        | Median 352 (SD 168)                 | Median 418 (SD 207)              | Median 185 (SD 180)                 |
| Quit treatment after giving birth     | 18.4% (n = 7)                       | 23.5% (n = 4)                    | 25% (n = 1)                        |
| **OB/GYN results**                   | %                                   | %                                | %                                   |
| Number of pregnancies                 | %                                   | %                                | %                                   |
| First time                            | (13) 34.2                           | (10) 58.8                        | (4) 100                             |
| Second time                           | (10) 26.3                           | (3) 17.6                         | (0) 0                               |
| Third or more                         | (15) 39.4                           | (4) 10.5                         | (0) 0                               |
| Pregnancy weeks at time of HIV diagnosis | Median 25.7 weeks (S.D. 8.1)     | Median 20 weeks (S.D. 9.8)       | Median 14.3 weeks (S.D. 6.7)        |
Table 1 (Continued)

| Variable                             | Without prior HIV diagnosis (N = 38) | With prior HIV diagnosis (N = 17) | Vertical transmission of HIV (N = 4) |
|--------------------------------------|--------------------------------------|----------------------------------|-------------------------------------|
| Pregnancy resolution                 | N%                                   | N%                               | N%                                 |
| Natural birth                        | (1) 2.6                              | (3) 17.6                         | (1) 25                              |
| C-section                            | (37) 97.3                            | (14) 82.3                        | (3) 75                              |
| OB/GYN complications                 |                                      | Premature birth due to severe     | Premature birth due to HELLP         |
|                                      |                                      | preeclampsia 5.8%                | syndrome 25%                        |
| Baby weight at birth (median)        | 2,663 g (SD 449)                     | 2,568 g (SD 424.9)               | 2,436 g (SD 568)                    |
| Birth planning method                | N%                                   | N%                               | N%                                 |
| Definitive (bilateral tubal          | (25) 65.7                            | (12) 70.5                        | (1) 25                              |
| obstruction)                         |                                      |                                  |                                     |
| Transdermal implants                 | (2) 5.2                              | (2) 11.7                         | (2) 50                              |
| IUD                                  | (6) 15.7                             | (0) 0                            | (1) 25                              |
| None                                 | (5) 13.1                             | (3) 17.6                         | (0) 0                               |
| HPV (cervical cytology)              | (4) 10.5                             | (6) 35.2                         | (1) 25                              |

Alicia Piñeirúa; Jeremy B Cruz; Steven Díaz and Andrea Gonzalez Rodríguez

1Clinica Especializada Condesa, Ginecología y Obstetricia, Mexico City, Mexico. 2Clinica Especializada Condesa, Médico de la Clínica Especializada Condes, Mexico City, Mexico. 3Clinica Especializada Condesa, Trabajo Social, Mexico City, Mexico. 4Clinica Especializada Iztapalapa, Médico de la Clínica Especializada Iztapa, Mexico City, Mexico. 5Clinica Especializada Iztapalapa, Infectología, Mexico City, Mexico. 6Clinica Especializada Condesa, Salud Mental, Mexico City, Mexico. 7Centro de Prevención y Atención Integral del VIH/sida de la Ciudad de México, Subdirector de Prevención e Información, México City, Mexico. 8Centro de Prevención y Atención integral del VIH/sida de la Ciudad de México, Directora Ejecutiva, Mexico City, Mexico.

Introduction: Condesa Specialized Clinic’s (CEC) OB/GYN area offers free diagnosis and treatment for women with HIV. In Mexico, HIV prevalence in pregnant women is 0.06% [1], and in CEC, it is 0.22%. The objective of this study is to describe a cohort of pregnant patients that received care at CEC.

Materials and methods: Transversal, descriptive study with a cohort of pregnant women with HIV at CEC, from August 2013 through October 2015. Patients were referred from public health centers with some clinics located in the subway stations who had a reactive rapid HIV test. At CEC, other diagnostic tests for HIV confirmation, HBV, HCV, syphilis, viral load (VL) and CD4 count were performed. Patients with reactive tests are immediately evaluated by OB/GYN for HAART; they have their VL measured weekly until an undetectable VL (<40 copies/mL) and then are evaluated monthly. At the 37th week, they are referred to a hospital for determination of birthing technique. Results: Of 69 pregnant women, 59 gave birth to a live baby. Of these, 38 were diagnosed with HIV during pregnancy (group 1) and 21 already had an HIV-positive diagnosis prior to becoming pregnant (group 2). In group 1, HIV diagnosis was established at week 25.7 (SD = 8) of pregnancy. In group 2, 42.8% had a VL < 40 when received notification of pregnancy; 42.1% of group 1 received RAL + TDF/FTC; 31.5% received ATV + TDF/FTC. About 58.6% of group 2 received ATV/lopinavar or LPV/r, and 23.5% received TDF/FTC/EFV. Nearly 73.6% and 100% of group 1 and group 2 had a VL < 40 at the end of the pregnancy, respectively; 94.7% of group 2 had a VL CV < 1000 copies; in two patients, virologic control was not achieved due to a late HIV diagnosis during pregnancy, and 97.3% of group 1 had a C-section birth versus 80.9% in group 2. The rest were natural births. 18.4% of group 1 and 23.8% of group 2 were lost to follow-up after birth. In those who continued treatment, there have not been any cases of vertical transmission of HIV reported. 89.4% of patient in follow-up have some kind of birth control method (Table 1).

Conclusions: HIV diagnosis in women in group occurs at advanced stages of pregnancy increasing the risk of vertical transmission. In Mexico, coverage of HIV testing during pregnancy is about 58% [2]. Better strategies must be implemented to increase the coverage of HIV testing in pregnant women.

References
1. Centro Nacional para la prevención y el control del VIH y el sida. Censida informa 2013. Mexico. 2. Eliminación de la transmisión materno-infantil del VIH y de la Sífilis en las Américas. Actualización 2015. Washington, DC: OPS, 2015: 19.

http://dx.doi.org/10.7448/IAS.19.2.21062

NON-AIDS MORBIDITY AND MORTALITY, AND AGING

P034

Are we doing enough preventive primary care for older HIV-positive patients? A survey in a third-level hospital in Mexico City

Brenda Crabtree-Ramírez; Juan Sierra-Madero; Carlos Madrigal-Iberri; María Jose Reyes-Fentanes and Yalin Caro-Vega

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Infectious Diseases, Mexico City, Mexico.

Introduction: Life expectancy of people living with HIV has increased as it has become a chronic manageable condition. Primary care preventive services play a crucial role in older patients with HIV infection given the higher incidence of co-morbidities when compared with non-HIV population. We aim to assess the frequency of screening tests for malignant and non-communicable diseases in HIV-positive patients >50 years seen at INCNMSZ in Mexico City before and after an intervention designed to improve awareness among physicians.
Methods: All HIV-positive patients aged > 50 years were included. The application of internationally recommended primary care screening tests [1] was reviewed in clinical charts. We evaluated the frequency of tests prescribed in the last year and at least once since patients became 50 years old. Factors associated with better screening practices (defined as more than 80% of screening performed as recommended) were analyzed. We developed a checklist of screening tests, as a reminder for physicians in each visit during a follow-up period of 12 months. Frequencies of tests before and after this intervention were compared.

Results: Of 1602, 355 (22%) patients were aged > 50 years, 84.4% were men with a mean age at HIV diagnosis of 45.6 years and a median time in care of 10.9 years (SD 5.94). Only 7.5% of patients had > 80% of non-communicable diseases related tests compared with 90% of complete HIV-care-related tests [1]. Of 1602, 170 (10.6%) patients had a CD4 count > 500 cells/mm3 and 1027 (62%) were on antiretroviral therapy, with median CD4 620/mm3 and 23 (79.3%) with suppressed viral load. Anal inspection was abnormal in 14 (36.8%) patients. Twenty-seven patients had a pathological cytology: 14 (36.8%) ASCUS, 12 (31.6%) LSIL, 1 (2.6%) HSIL and 9 (23.7%) normal cytology. Two samples were unrepresentative. The molecular diagnosis of HPV was positive in 23 (65.8%) patients, negative in 6 (17.1%) patients and 80% of non-communicable diseases related tests compared with 90% of complete HIV-care-related tests [1]. Of 1602, 170 (10.6%) patients had a CD4 count > 500 cells/mm3 and 1027 (62%) were on antiretroviral therapy, with median CD4 620/mm3 and 23 (79.3%) with suppressed viral load. Anal inspection was abnormal in 14 (36.8%) patients. Twenty-seven patients had a pathological cytology: 14 (36.8%) ASCUS, 12 (31.6%) LSIL, 1 (2.6%) HSIL and 9 (23.7%) normal cytology. Two samples were unrepresentative. The molecular diagnosis of HPV was positive in 23 (65.8%) patients, negative in 6 (17.1%) patients and

Conclusions: Cancer and osteoporosis screening were underperformed. Lipids, glucose and blood pressure were done following recommendations. Only cardiovascular risk assessment improved after our intervention. Barriers to improve preventive primary care practices in older HIV-positive patients need further evaluation.

Reference
1. Aberg JA, Gallang JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA., Primary Care Guidelines for the Management of Persons Infected with HIV. Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2013;2013:1–34.

http://dx.doi.org/10.7448/IAS.19.2.21063
unrepresentative in 6 (17.1%) patients. The genotypes found in 11 patients were 6, 11, 16, 18 and 54. Anoscopy was performed in 15 (55.5%) of 27 patients with indication for it: 9 without macroscopic alteration and 6 pathological (condilomatosis). HPV detection was positive in 18 (78.35%) HIV-positive patients and 5 (21.7%) HIV-negative patients ($p = 0.555$). Cytology was abnormal in 23 (85.2%) HIV-positive patients (14.8%) and 4 HIV-negative ($p = 0.064$).

**Conclusions:** A high prevalence of HPV infection and pathological anal cytology was found in the population studied, especially in HIV-positive patients. These results are similar to the ones found in international data and will help to develop national strategies of prevention through the implementation of screening.

**References**

1. Conley LJ, Bush TJ, Darragh TM, Palefsky JM, Unger ER, Patel P, et al. Incidence and predictors of abnormal anal cytology findings among HIV-infected adults receiving contemporary antiretroviral therapy. J Infect Dis. 2016;213(3):351–60.

2. Machalek D, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012;13:477–500.

3. Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, et al. Forum Group Members; Bethesda 2001 Workshop. The 2001 Bethesda system. Terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–9.

http://dx.doi.org/10.7448/IAS.19.2.21064

P036

**Analysis of HIV/AIDS mortality in Mexico by state and municipal levels from 2003 to 2013**

Enrique Bravo-García1 and Hilda Ortíz-Pérez2

1Spectrum: Educación, Salud y Sociedad, A.C., President, Mexico City, Mexico. 2Departamento de Atención a la Salud, Universidad Autónoma Metropolitana – Xochimilco, Mexico City, Mexico.
Introduction: Since 2003, Mexico has a policy of free and universal access to treatment for HIV/AIDS. At the end of 2013, a total of 89,000 persons were receiving highly active antiretroviral therapy (HAART). However, from 2003 to 2013, 54,140 persons have died from AIDS. The death rate for HIV/AIDS has not decreased as expected, reducing only from 4.4 deaths per 100,000 inhabitants in 2003 to 4.2 per 100,000 in 2013. The aim of the present study was to analyze the distribution of AIDS mortality according to state and municipal levels, with the purpose of identifying the sites where resources should be targeted to reduce HIV/AIDS mortality in Mexico.

Materials and methods: We estimate the increase and decrease in the death rate from HIV/AIDS by state from 2003 to 2013 and the average annual HIV/AIDS mortality rate among 2,437 municipalities in Mexico from 2009 to 2013. Considering only the municipalities with 20,000 or more inhabitants, we selected 25 municipalities with the highest mortality rates. The information for these calculations was obtained from INEGI and CONAPO, institutions providing official figures of population and mortality, respectively.

Results: In 2013, the states with the highest AIDS mortality rates were: Tabasco (10.58 per 100,000 inhabitants), Quintana Roo (9.02) and Veracruz (8.65). In contrast, Zacatecas (1.03), Guanajuato (1.43) and Hidalgo (1.92) recorded the lowest rates. The difference between the states with the highest and lowest rate (Tabasco and Zacatecas) is more than seven times. It is important to emphasize that, from 2003 to 2013, in 50% of Mexican states (16/32) the AIDS mortality rate increased, rather than decreased (Figure 1).

The 25 municipalities with the highest death rate from AIDS are located in five states, all of them in the Southeast (Veracruz, Chiapas, Tabasco, Campeche and Oaxaca). The municipality of Carlos A. Carrillo, Veracruz, ranked one with a rate of 39.6 HIV/AIDS deaths per 100,000 inhabitants (nine times higher than the national rate), and Poza Rica, Veracruz, ranked 25 with a rate of 13.4 HIV/AIDS deaths per 100,000 inhabitants (three times higher than the national rate) (Figure 2).

Conclusions: Data highlight the need for enhanced HIV detection and treatment for 25 municipalities with the highest AIDS mortality rates, as well as the states most affected. Findings can help to apply interventions to link and retain in care persons until they are virologically suppressed. It is urgent to reduce AIDS mortality in Mexico.

http://dx.doi.org/10.7448/IAS.19.2.21065

TREATMENT STRATEGIES AND OUTCOMES

P037

Significant increase in new HIV infections among young adults in Latin America

Carlos Gallo1; Olga Lopez2; Carolina Chahin3; Beatriz Marinovich4; Pedro Zitko4 and Carlos Beltran1

1Latin American HIV Workshop Study Group, AIDS, Arica, Chile. 2Latin American HIV Workshop Study Group, AIDS, Iquique, Chile. 3Latin American HIV Workshop Study Group, Temuco, Chile. 4Latin American HIV Workshop Study Group, AIDS, Santiago, Chile.

Introduction: The WHO/UNAIDS 2.0 initiative and its 90-90-90 goal aim to reduce new HIV infections by 90% through a significant increase in diagnosis, care and ART of HIV-positive populations around the world. Most Latin American countries launched expanded access to ART a long time ago but showed low rates of diagnosis of HIV-positive people which explains, at least in part, the modest 3% reduction in new infections in the region as compared to a 38% global reduction and more than 50–75% reduction in some countries.

Materials and methods: The Latin American Workshop Study Group is an expanding network of 38 HIV care centres from 11 countries of South America, Central America, the Caribbean and Mexico with clinical data from 73,431 patients up to September 2015, 7,732 of them being new 2013/2014 HIV cases. Age and gender distributions were analyzed globally and by participating centres and countries. Statistical analysis was done by chi-square test.

Results: Among new HIV infections, 33.8% were 15–29 years old. This is the largest age group in all countries except Argentina with wide differences between centres in each country. 79.4% of new cases were men, with 34.5% of them 15–29 years old, and 20.6% were women, with 31.0% of them 15–29 years old (p < 0.01). On the
Contrary, 14.1% of new HIV infections occurred in men older than 50 years as compared with 18.1% of new cases in women older than 50 years. In a sub-analysis in Chile, the largest increase in new cases among people younger than 30 years was observed between the age of 15 and 24 years.

Conclusions: A modest reduction in new HIV infections has been reported in Latin America. Young people especially men between 15 and 24 years show an important increase in new HIV cases during 2013–2014 in most countries in spite of some differences between the centres. In the context of the 90-90-90 goal, specific policies should be implemented targeting this key population.

http://dx.doi.org/10.7448/IAS.19.2.21066

P038
Presentation to care with advanced HIV disease is still a problem in Latin America
Ana Paulina Celi1,a; Maria Greco2,b; Ernesto Martinez3; Carmen Vargas4; Francisco Belaunzaran Zamudio5 and Fernando Mejia6
1Latin American HIV Workshop Study Group, AIDS, Quito, Ecuador. 2Latin American HIV Workshop Study Group, AIDS, La Plata, Argentina. 3Latin American HIV Workshop Study Group, AIDS, Cali, Colombia. 4Latin American HIV Workshop Study Group, AIDS, San Jose, Costa Rica. 5Latin American HIV Workshop Study Group, AIDS, Mexico City, Mexico. 6Latin American HIV Workshop Study Group, AIDS, Lima, Peru.

Introduction: Presentation to care with advanced HIV disease, defined as first CD4 count below 200 cells/mm3, has been reported previously between 38 and 45% by PAHO, CCASAnet and the Latin American Workshop Study Group with significant differences between countries. The UNAIDS/WHO 2.0 initiative, beside 90-90-90 goal, aims to reduce late presentation to ART to 10% of new cases and at a general level.

Materials and methods: The Latin-American Workshop Study Group is an expanding network of 38 HIV care centres form 11 countries of South America, Central America, the Caribbean and Mexico with clinical data from 73,431 patients up to September 2015, 6,072 of them being new 2013–2014 HIV cases. Late presentation to care was analyzed globally, by gender, age and by participating centres and countries according to the first CD4 count and the clinical stage at the first visit. Statistical analysis was done by chi-square test and odds ratios.

Results: Among new HIV infections, 37.0% presented to care with a CD4 count below 200 cells/mm3 and an additional 23.1% with a first CD4 count between 200 and 350 cells/mm3. 52.1% had diseases defining B or C stage. 37.5% of men and 35.1% of women presented with a CD4 count below 200 cells/mm3 (p < 0.01; OR 0.26 for very late presentation among women). Late presentation was strongly associated to age at presentation. People younger than 30 years had the lowest risk for late presentation (p < 0.01). Differences between countries remain.

Conclusions: Very late presentation to care is a direct consequence of insufficient testing in Latin America. A very modest reduction in presentation to care with less than 200 cells/mm3 has been observed in new HIV cases in 2013–2014 in all countries in spite of some differences between centres. Women and people younger than 30 years have the lowest risk for presentation to care with advanced HIV disease. Strategies for increase in testing should address the higher prevalence in key populations but also promotion of testing in people at risk for late presentation.

http://dx.doi.org/10.7448/IAS.19.2.21067

P039
Dolutegravir-based regimens (DBRs) viral load decay at week 4 could predict sustained viral suppression at week 96
Rolina Quercia1; Steve Almond2; Tia Vincent1; Alicia Aylott3; Michael Aboud4 and Jessica Lim3
1ViiV Healthcare, Medical Department, London, UK. 2Bayer, Mississauga, Canada. 3Glawsworth, Stockley Park, UK.

Introduction: The medium- or long-term implications of rapid viral load early-phase decay, during integrase inhibitor-based therapy, are not fully understood. This analysis was conducted to assess the predictive value of rapid virological response (RVR) at week 4 on sustained virological response (SVR) at week 96, in naïve subjects treated with dolutegravir-based regimens (DBRs).

Materials and methods: Post hoc cross-sectional analysis of subjects enrolled in the naive dolutegravir (DTG) Phase 3 clinical trials, SPRING-2 [1] and FLAMINGO [2]. RVR and SVR were assessed at weeks 4 and 96, respectively based on HIV-1 RNA < 50 as determined by FDA snapshot. Positive predictive values (PPVs) and negative predictive values (NPVs) were calculated: PPVs as the proportion of subjects suppressed at week 4 who were also suppressed at week 96 and NPVs as the proportion of subjects not suppressed at week 4 who were also not suppressed at week 96.

Results: A total of 2,139 subjects were analyzed including those receiving DBRs and comparator arms. The analysis revealed that 70% of the subjects receiving DBRs achieved RVR at week 4, 80% attained SVR at week 96. PPVs and NPVs of SVR in the DBR study population were 85 and 29%, respectively. The DBRs’ PPV was numerically higher than for Efavirenz (EFV) or Darunavir/ritonavir (DRV/r) plus 2 nucleosides (Nucs), and similar to that with Raltegravir (RAL) plus 2 Nucs. The NPV with RAL was numerically higher than with DBRs, reflecting that more DBR subjects without RVR ended with SVR.

| SVR at W96 | SINGLE DTG EFV | SPRING – 2 DTG RAL | FLAMINGO DTG DRV/r |
|-----------|---------------|-----------------|-----------------|
| PPV (%)   | 87—73         | 84—85           | 82—70           |
| NPV (%)   | 32—28         | 28—39           | 26—32           |

Conclusions: This analysis shows high rates of RVR with DBRs at week 4, translated into high PPV, suggesting potential predictability of week 4 RVR on SVR. Further analysis of long-term data would be key to support the relationship between early and long-term response. Higher RVR with DBRs, associated with high PPV for SVR, may have implications for early monitoring frequency.

References
1. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13:927—35.
2. Wallmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khouny-Joses MA, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015;70(5):515—9.
3. Molina JM, Ciotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2(4):e127—36.
PO40
Clinical monitoring system of people living with HIV/AIDS (SIMC): Brazilian strategy to reduce GAP treatment
Marihá Moura; Ana Kolling; Marcelo Freitas; Ana Roberta Pascom; Adele Benzaken and Fabio Mesquita
Department of STD/AIDS and Viral Hepatitis, Ministry of Health of Brazil, Brasilia, Brazil.

Introduction: Brazil published a normative protocol in 2013 implementing the “Treatment for All,” being the first developing country to recommend highly active antiretroviral therapy (HAART) for all people living with HIV/AIDS (PLWHA), regardless of CD4 and viral load. At the end of 2014, there were 781,000 PLWHA in Brazil, representing a prevalence rate of HIV of 0.39%. Of these, 83% were diagnosed and 52% started HAART. However, only 62% of the diagnosed PLWHA are on HAART, a major challenge of Brazil against AIDS epidemic.

Materials and methods: In order to expand HAART coverage, Brazilian Ministry of Health developed in 2013 a clinical monitoring system (SIMC) from data of the logistics and laboratory control systems. SIMC shows treatment GAP and monthly monitors the inclusion of these patients into treatment. Treatment GAP means PLWHA who did CD4 and viral load tests and are not on HAART. According to the Brazilian’s Treatment Guideline, all people with HIV have indication of HAART, regardless of CD4.

Results: Ministry of Health’s technicians were responsible for monitoring, locally or at distance, estates and municipalities in their GAP elimination strategies.

Conclusions: SIMC is an effective monitoring tool that allows services to identify GAP treatment and conduct active surveillance of patients for starting HAART. Since SIMC implementation, GAP decreased from 32.5% to 29%. A general reduction was observed in relation to age groups of PLWHA throughout the analysis period, with age group 18–24 having largest GAP (43.4%) (Figure 1). A total of 15 states retain GAP over the national average (29%) (Figure 2). These results allow focusing on upcoming interventions in places with the greatest difficulties to reduce GAP, considering the need to invest in actions aimed at young people and to scale up access to treatment.

http://dx.doi.org/10.7448/IAS.19.2.21069

PO41
Low-level viraemia in people living with HIV at antiretroviral therapy
Marisol Valenzuela-Lara; Carlos Magis Rodríguez; Eduardo Becerril-Vargas and Eddie Antonio León Juárez
CENSIDA, DAI, Mexico City, Mexico.

Introduction: HIV viraemia is recognized as a significant prognostic indicator of disease progression in HIV-1-positive patients, and HIV viral load (VL) acts as a marker for treatment response. The goal of antiretroviral therapy (ART) is to reduce viral load to undetectable levels, below 50 copies/mL. However, these goals are not always achieved. Some patients experience persistent low-level viraemia (LLV), which may be considered as a significant prognostic indicator of virologic failure and promotes the selection of drug resistance mutations. Low-level viraemia is defined as VL between 50–200 copies/mL HIV-1 RNA.

Materials and methods: The objective of this study was to estimate the prevalence of LLV in people with HIV who recently initiated antiretroviral therapy at the Ministry of Health of Mexico. A total of 3,091 patients were studied; they were under first-line therapy and reached 24 weeks under treatment in 2015 with a subsequent VL. VL results were related to clinical data retrospectively including ART-composition, and they were subdivided into non-nucleoside reverse transcriptase inhibitors (NNRTIs) (Efavirenz) and protease inhibitors (Pis) (Atazanavir, Darunavir, Lopinavir). Patients were classified into four groups: <50 copies/mL, 50–200 copies/mL, 201–500 copies/mL and >501 copies/mL.
Results: Success of therapy was defined as <50 copies/mL and was observed in 407 (76.5%) women and 2,088 (81.6%) men; the difference observed was statistically significant ($p < 0.0001$). A bivariate analysis showed that men had a higher probability of achieving success than women (OR 1.36; CI 95% 1.08 to 1.71; $p < 0.0068$).

The prevalence of LLV in women and men was 7.3 and 10.1%, respectively, and 9.6% for both sexes (Figure 1). The amount of patients with LLV differed significantly between NNRTI-based first-line regimens (9.17%) and PI-based regimens (11.62%) ($p < 0.0001$); a bivariate analysis showed that patients on NNRTI-based regimens had a higher probability of achieving <50 copies/mL (OR 1.66; CI 95% 1.34–2.06; $p < 0.00001$). When data were subdivided into ART-composition and sex, the difference between sexes were not statistically significant for NNRTI-based regimens ($p = 0.418$), but they remain statistically significant for PI-based regimens ($p < 0.0001$) (Figure 2).

Conclusions: Regimens containing an NNRTI plus two NRTIs have been shown to suppress VL to lower HIV-1 RNA copy numbers compared to those with two NRTIs plus PIs, with important gender differences that have impact on women’s ART outcomes.

http://dx.doi.org/10.7448/IAS.19.2.21070

Abstract P040—Figure 2. Proportion of PLWHA eligible for HAART who did not start treatment (GAP) by age group. Brazil, 2009–2015.

Abstract P041—Figure 1. Low-level viraemia prevalence after 24 weeks on ART at Mexico MoH, 2015.
P042
Persistency of first-line ART in a real-world setting in a cohort of HIV-positive patients from Santiago, Chile
Leonardo Chanqueo; Fernando Bernal; Patricia Vásquez; Catalina Gutierrez; Carolina Giadalah and Michel Serri
Hospital San Juan de Dios, Servicio de Medicina, Santiago, Chile.

Introduction: Prolonging ART regimen durability is a key to achieving long-term treatment success in the management of HIV-positive patients. However, risk factors such as frequency of dosage, complexity of regimens and medication side effects may result in the discontinuation of ART. The aim of this study was to estimate the persistence of the most commonly used first-line ART regimens used in HIV-positive adults in Chile and the most common causes of changed ART in our cohort.

Materials and methods: Using retrospective data from our cohort of HIV-positive patients from Santiago, Chile, we included naïve patients. Using restrospective data from our cohort in Chile and the most common causes of changed ART in our cohort.

Most commonly used first-line ART regimens used in HIV-positive adults of treatment. The aim of this study was to estimate the persistence of the following regimens: fixed-dose backbone (ABC/3TC, TDF/FTC or ZDV/3TC) plus EFV, ATV/r or LPV/r. The cumulative incidence of treatment change was calculated at 18 months. In addition, the distribution of the reasons for changing was calculated in patients who changed their initial ART regimen.

Results: A total of 282 ART-naïve patients were included; 85% were male (80% men who have sex with men) and 15% female. A total of 104 (36.9%) started with ZDV/3TC, 99 (35.1%) with ABC/3TC and 79 (28%) with TDF/FTC as a backbone. The most commonly prescribed third drug was EFV (173, 61.3%) followed by ATV/r (59, 20.9%) and LPV/r (50, 17.7%). At 18 months of ART, 70% of the patients maintained the same regimen. Twice a day (BID) regimen was associated with a higher risk of treatment change compared with QD regimen; TDF/FTC plus (EFV or ATV/r) and ABC/3TC plus (EFV or ATV/r) regimens had a cumulative incidence of treatment change at 18 months of 0.148/0.197 and 0.214/0.250, respectively. However, BID regimens such as ZDV/3TC plus (EFV, ATV/r or LPV/r) had a cumulative incidence of treatment change at 0.483/0.400/0.516, respectively. The reasons for treatment change were toxicity/adverse event (n = 62, 66.1%) – hematologic toxicity (n = 23, 25%), skin rash (n = 13, 14%) and CNS side effects (n = 11, 12%) – followed by simplification (n = 12, 14%) and treatment failure/resistance (n = 5, 6.5%).

Conclusions: HIV patients initiating first-line ART with QD regimen are more likely to be persistent with the same therapy than those beginning treatment with BID regimen. Toxicity remains the main reason for discontinuing ART. Discontinuation and switching of initial ARV regimens are still frequent. Therefore, the choice of an easy and non-toxic ARV regimen for initial therapy is the most important issue in the care of our HIV patients.

http://dx.doi.org/10.7448/IAS.19.2.21071

P043
48 weeks CD4 cell recovery in HIV-positive patients on effective antiretroviral treatment
Guillermo Viloria; Mariana Kundro; Javier Tolbaro and Marcelo Losso
J.M. Ramos Mejia, Servicio de Inmunocomprometidos, Buenos Aires, Argentina.

Introduction: The CD4+ cell counts recovery in HIV-positive individuals receiving antiretroviral therapy (ART) shows high variability. We aimed to evaluate the factors associated with successful CD4 recovery in the first year of treatment in a cohort of patients on effective ART.

Materials and methods: We reviewed medical records of all naïve outpatients for whom ART was started between January 2008 and December 2014 in our unit. Pregnant women were excluded. CD4 recovery was defined as an increment > 100 cells/μl in the first year of therapy, and effective treatment as the achievement of HIV-RNA < 50 cop/ml. Logistic regression was used to examine the factors associated with CD4+ cells recovery.

Results: A total of 463 patients started ART during the study period, of whom 418 (90%) achieved virologic suppression. Nine patients (1.9%) died. Data on CD4 recovery were available for 338 (82%) patients. Overall, 67.1% (227/338) of patients were male, median age was 41 years (IQR: 35–48), baseline CD4+ count was 183 cells/μl (IQR: 87–250) and median CD4+ gain at 48 weeks 196 cells/μl (IQR: 102–301). The proportion of patients with a successful immune recovery was 75% (256/338). It was higher in males [OR 1.88; 95%CI, 1.13-3.33, (p = 0.01)]; whereas co-infection with HCV [OR, 0.12; 95% CI, 0.05–0.28 (p < 0.001)] and use of intravenous drugs (IVDU) [OR, 0.25; 95% CI, 0.07–0.85 (p = 0.026)] were associated with a reduced likelihood of attaining a CD4+ cell gain > 100 cells/μl. Age, baseline CD4+ cell count, heterosexual (vs. homosexual) transmission, NNRTI (vs. PI)-based regimens and AIDS events were not associated with CD4+ recovery in this cohort.
Conclusions: We found that a successful immune recovery is feasible in most of naïve patients at 48 weeks of effective antiretroviral therapy, even in those who start ART with low CD4+ cell counts or AIDS events. IVDU and HCV co-infection were deleterious for CD4+ reconstitution in our cohort. We did not found differences in CD4+ recovery with the use of PI- or NNRTI-based regimens.

http://dx.doi.org/10.7448/IAS.19.2.21072

PO044
Prevalence of HIV-1 drug resistance associated mutations in patients experiencing first-line antiretroviral therapy failure in a cohort of HIV-positive patients from Santiago, Chile, 2012–2014
Fernando Bernal; Leonardo Chuanqueo; Catalina Gutierrez and Patricia Vásquez
Hospital San Juan de Dios, Servicio de Medicina, Santiago, Chile.

Background: Antiretroviral therapy (ART) has dramatically decreased morbidity and mortality among HIV-1-positive patients through the durable suppression of viral replication to undetectable levels. However, the efficiency of these treatments can be compromised by the presence of drug resistance-associated mutations (DRMs), resulting in virological failure. Although international guidelines, such as those of the UK and the US, recommend a basal genotypic HIV resistance testing, in Chile this standard-of-care management test is recommended only in patients who experienced virological failure on first-line ART. The aim of this study was to estimate the prevalence of HIV-1 DRMs in patients experiencing first-line ART failure in a cohort of adults HIV-positive patients from Santiago, Chile.

Materials and methods: Using retrospective data from our cohort from Hospital San Juan de Dios de Santiago, Chile, we included all the HIV genotypic testing request forms from adult HIV patients with ART failure—defined as a plasma viral load (VL) >1,000 RNA copies/ml—between 2012 and 2014 who initiated ART according to the Chilean HIV treatment guideline. The frequency of DRMs was analyzed from the HIV genotypic test reports, which were done by ViroSeq HIV-1 Genotyping System at the Chilean HIV reference laboratory (Laboratorio de Biología Molecular – Hospital Lucio Córdova, Santiago).

Results: There were 20 requests for HIV genotypic resistance tests in 2012, 77 in 2013 and 79 in 2014. A total of 168 HIV genotypic resistance tests were requested; 134 (80%) were analyzed and 34 (20%) rejected because the viral load was lower than 1,000 RNA copies/ml. We determined that 99/134 (74%) patients had viruses harbouring DRMs. Among them, 69 (70%) patients had two-class resistance (nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI)). The most common NRTI and NNRTI DRMs detected were the M184V and K103N; M230L was detected only in three patients. Major PI mutations were found only in 3.82% of patients (4/99).

Conclusions: Our findings emphasize the importance of using the genotypic test at the first treatment failures to guide the choice of an effective alternative regimen. In addition, our study gave insights on the distribution of DRMs in our population which are related to the initial ART regimen used. Two-class resistance (NRTI plus NNRTI) was very frequently developed, but major PI-mutations were infrequently detected and no etravirine or rilpivirine DRMs were found in patients who experienced virological failure on first-line ARV in our cohort.

http://dx.doi.org/10.7448/IAS.19.2.21073

PO045
Ledipasvir/sofosbuvir (LDV/SOF) for 8W in genotype 1 treatment-naïve (TN) non-cirrhotic (NC) patients with viral load (VL) less than 6 million IU/ML; a comparative analysis of the ION-3 data to real world effectiveness
Joshua Feld; Peter Buggisch; Jorg Peterson; Stefan Mauss; Kristowdley; Michael Curr; Peter Ruane; Dan Ains; Naokyo Tsai; Yoori Lee; Edward Eggelton; Macky Natha; Bruce Kretter; Diana Brainard; Nelson Cheinquers and Patrick Ingiliz
1Toronto Centre for Liver Disease, University of Toronto, Toronto, Canada. 2Asklepios Klinik St. Georg, IFI Institut für Interdisziplinäre Medizin, Hamburg, Germany. 3Center for HIV and Hepatogastroenterology, Düsseldorf, Germany. 4Swedish Medical Center, Seattle, USA. 5Beth Israel, Boston, USA. 6Ruane Medical and Liver Health Institute, Los Angeles, USA. 7Queens Medical Center, Honolulu, USA. 8TRIO Health Analytics, Newton, USA. 9Gilead Sciences, Los Angeles, USA. 10Medical Affairs, Gilead Sciences, Foster City, USA. 11Gilead, Public Health and Medical Affairs, Sao Paulo, Brazil. 12Medizinisches Infektiologie Zentrum, Berlin, Germany.

Introduction and aims: The optimal duration of therapy to achieve sustained virological response (SVR) depends on multiple factors. Patients treated with ledipasvir/sofosbuvir (LDV/SOF) with 8–24 weeks achieved SVR12 from 94 to 100% in the ION Phase 3 studies. A decision to shorten therapy to 8 weeks is based on treatment history, cirrhosis status and baseline VL. In a post hoc analysis of the ION-3 (treatment-naïve (TN) non-cirrhotic (NC) patients) 8-week data, a viral load (VL) <6 million was shown to be the best predictor of SVR. Real world effectiveness (RWE) is often different from Phase 3 trials and there is a need to understand real-world 8-week regimens in a broader spectrum of patients.

Abstract P045—Table 1. Demographic data and results from clinical trials and RWE studies using LDV/SOF for 8 weeks

| Study | ION-3 | TARGET | TRIO | Buggisch | GECCO | VA – Marshall | Ruane | Total (non ION3) |
|-------|-------|--------|------|----------|-------|---------------|-------|------------------|
| N/N (GT 1) | 119/123 | 150/154 | 251/263 | 103/103 | 69/70 | 47/48 | 18/20 | 638/658 |
| Age (mean) | 52 (22-73) | 58* (19-84) | 57 (18-84) | 50* (22-77) | 52* (44-58) | 61 (32-75) | 52 (35-66) | n/a |
| HIV/HCV | 0/1 | 1/2 | 3/3 | 3/3 | 7/7 | 0 | 18/20 | 32/34 |
| VL >6 million | 0 | 0 | 8/8 | 0 | 9/9 | 0 | 0 | 17/17 |
| Cirrhotics | 0 | 6/6 | 0 | 0 | 3/3 | 0 | 0 | 9/9 |
| GT 4 | 0 | 0 | 0 | 2/2 | 0 | 0 | 0 | 2/2 |
| Tx Exp | 0 | 8/8 | 0 | 1/1 | 12/12 | 5/5 | 0 | 26/26 |
| SVR12 (%) | 97% | 97% | 95% | 100% | 99% | 98% | 90% | 97% |

*Median age used

http://dx.doi.org/10.7448/IAS.19.2.21073
Methods: RWE 8-week LDV/SOF data are emerging from multiple single-centre and multicentre retrospective and prospective cohorts. In this analysis, the Phase-3 ION-3 data are compared with data from several diverse real-world populations and one post-marketing investigator sponsored HIV/HCV trial. Patient demographics, characteristics, SVR12 and discontinuation data have been collated and compared. Results: The ION-3 post hoc analysis reported 123 patients who were TN, NC (VL <6 million) and treated with 8 weeks of LDV/SOF. Mean age was 52 y, 22% were black, 72% had GT1a and the overall SVR12 was 97% (119/123). The overall SVR12 rate from six diverse real-world and post-marketing cohorts was also 97% (638/658). There was no significant impact of HCV genotypes or subtypes (GT1a, 1b versus GT4), prior treatment history, presence or absence of cirrhosis, high viral load (HCV VL >6 million) or HCV/HCV co-infection. All response rates are detailed in Table 1. Conclusions: LDV/SOF for 8 weeks yielded high SVR rates in ION-3. Analysis of RWE data from several diverse and heterogeneous cohorts from the United States and Europe shows SVR outcomes that were consistent with the Phase-3 ION-3 results and supports the use of 8 weeks LDV/SOF in treatment-naïve, non-cirrhotic GT1 patients with a baseline HCV VL <6 million and possibly in other populations including HCV/HCV co-infected patients. Discontinuation rates were low despite diverse patients and clinical settings. Data from the TARGET and TRIO cohorts also suggest that the 8-week regimen is under-utilized.

http://dx.doi.org/10.7448/IAS.19.2.21074

PO46
Characterization of a large hepatitis C patient cohort in a reference centre in Brazil: a descriptive cohort study
Rosario Quiroga; Andra Machado Luiz; Fatuma Ca Odongo; Maria Laura M De Matos; Ana Catarina Nastr; Aleia Faustina Campos; Ligia Capuani and Maria Cassia Mendes-Correia Medical School – São Paulo University, Infectious Diseases, São Paulo, Brazil.

Introduction: Chronic Hepatitis C (CHC) affects approximately 2.7 million people in Brazil [1]. Until December 2015, the majority of patients have been treated with interferon-based therapy [2]. The use of direct acting agents (DAAs) in Brazil has been recently introduced and only for patients with severe liver disease [3].

Objectives: The objectives of the present study were: 1) To describe the results of the clinical characteristics of CHC patients attended at a reference centre in Brazil; 2) To identify patients who are yet to be treated; 3) To differentiate easy-to-treat from difficult-to-treat patients.

Materials and methods: We developed a retrospective and descriptive cohort study at Hospital das Clínicas, which is a public hospital and a reference centre to treat CHC in São Paulo, Brazil. The enrolled patients were selected from those registered at the Infectious Diseases Division. Medical records from all patients with CHC were reviewed in order to analyze selected variables: age, gender, HIV co-infection, HCV genotype, stage of liver fibrosis (by using Metavir Score and/or evidence of portal hypertension) and information regarding previous hepatitis C treatment. In this study, difficult-to-treat patients were defined as follows: experienced genotype 3-infected or genotype 1-infected patients who failed first-generation protease inhibitors, cirrhotic or HIV co-infected patients.

Results: Between April 2015 and December 2015, 1,757 patients with CHC were identified and included in our data bank. Of these patients, 219 (12.4%) had HIV co-infection. 893 (50.8%) were women, and mean age was 41.95 ± 14.5 years. Genotype 1 predominated with 972 (55.3%) cases. Genotype 2, 3, 4 and 5 were 50 (2.85%), 513 (29.2%), 11 and 1 cases, respectively. Among all patients, 747 (42.5%) were F3 or F4, and 293 (16.6%) had cirrhosis. Among all patients, 1,048 (59.6%) had received previous hepatitis C treatment, with interferon-based therapy (n = 901, 86%) or telaprevir/boceprevir-based therapy (n = 147, 14%). Among 1,048 previously treated patients, only 480 (46%) obtained sustained virologic response (SVR) at a previous treatment and 250 were genotype 3 patients. Among all included patients, 1,277 (73%) were yet to be treated and only 660 (37.5%) were considered difficult-to-treat patients.

Conclusions: In this Brazilian cohort from an urban tertiary medical centre, the majority of patients still wait for a proper HCV treatment. Less than half of those treated prior to DAAs had an SVR. However, the majority of patients in the cohort were considered easy-to-treat patients.

References
1. Pereira LM, Martelli CM, Moreira RC, Merchán-Hamman E, Stein AT, Cardoso MR, et al. Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect. Dis. 2013;13:60.
2. Ferreira PR, Brandão-Mello CE, Estes C, González Júnior FL, Coelho HS, Razavi H, et al. Disease burden of chronic hepatitis C in Brazil. Braz J Infect Dis. 2015;19(4):363–8.
3. Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfeções. http://www.aids.gov.br/publicacao/2015/protocolo-clinico-e-diretrizes-terapeuticas-para-hepatite-c-e-coinfeccoes. Acess January 2016.

http://dx.doi.org/10.7448/IAS.19.2.21075

PO47
High prevalence of occult hepatitis B virus infection among blood donors with anti-hepatitis B core antibodies in the north-east region of Colombia
Henry Bautista-Amorocado1; Yeny-Zulay Castellanos-Dominguez1; Sandra-Lucia Saavedra-Cortés2; Vianney Portilla-Rodríguez2; Leonor Chacón-de-Mendieta2 and Ana-Elvira Farfán-García2
1Universidad de Santander – UDES, Bacteriología y L.C. – ClínicoUDES Research Group, Bucaramanga, Colombia. 2Laboratory of Public Health of the Province of Santander (LPHPS), Blood Bank Network, Bucaramanga, Colombia.

Introduction: Infection by hepatitis B virus (HBV) can occur through blood transfusions when routine screening of hepatitis B surface antigen (HBsAg) is negative. The aim of this study was to evaluate the seroprevalence of HBV infection and to identify occult hepatitis B infection (OBI) among donors with only antibodies against the hepatitis B core (anti-HBc).

Materials and methods: A cross-sectional study was carried out in three blood banks in Bucaramanga city, Colombia, in 2013. Demographic and epidemiological information was collected from each donor, whereas HBV serological markers and DNA were investigated in serum by immunoassays and nested-PCR, respectively. A 1085 nucleotide fragment overlapping the s gene of hepatitis B virus was sequenced after cloning in a sequencing plasmid to identify the viral genotype.

Results: In total, 61,188 blood donors were gathered during the study period, 45.2% were first-time volunteers and 57.9% were male. HBV serological markers were detected in 1,215 blood donors (2%), from which 0.2% were HBsAg(+) and 1.8% anti-HBc (+)/HBsAg(-). Differences were observed for types of blood donor, sex and age group with anti-HBc (+)/HBsAg(-) donors (p < 0.001). OBI was detected in 7.3% of the donors with anti-HBc (+) antibodies from which 75% were anti-HBc (+)/anti-HBs (+) serological profile. Genotype F, subtype F3 was identified in all OBI donors. Only one mutation was found in a blood donor, specifically a serine-leucine non-conservative change in codon 143 (S143L).

http://dx.doi.org/10.7448/IAS.19.2.21095
Conclusions: The 7.3% of OBI among donors with anti-HBc(+) antibodies in the north-east region of Colombia is the highest prevalence reported in blood banks of Latin America so far. As expected, F3 is the predominant viral subtype circulating in the country with low mutation rate inside the s gene. Molecular assays should be included in the screening for infectious diseases to reduce the risk of HBV transmission through blood donation.

http://dx.doi.org/10.7448/IAS.19.2.21076

P048
Viral hepatitis and syphilis prevalence in persons who performed premarital blood tests in Argentina
Patricia Angelen1; Valeria Levite1; Gabriela Vidiella1; Joaquin Solar1; Ema Cornelli2; Dan Adaszko3; Ariel Adaszko3; Cecilia Moyano5; Diosnel Bouclet1; Hector Cuello1; Viviana Molfese5; Rosario Skarzauskas3; Maria De Los Angeles Pando6 and Carlos Falistocco1
1National AIDS and STIs Program, National Ministry of Health, Buenos Aires, Argentina. 2Statistical Area, Ministry of Health, Santa Fe, Argentina. 3HIV/AIDS & Viral Hepatitis Provincial Program, Cordoba, Argentina. 4Central Hospital, Mendoza, Argentina. 5HIV/AIDS & Viral Hepatitis Provincial Program, Buenos Aires, Argentina. 6INBIRS, University of Buenos Aires, Buenos Aires, Argentina.

Introduction: Viral hepatitis and syphilis are important public health issues on which Argentina has no prevalence data in the general population. Prevalence studies are fundamental pillars to develop strategies for their control, contributing with knowledge about the needs for prevention, testing and treatment.

Materials and methods: A cross-sectional study was designed with a cluster sampling strategy. People who attended health services in occasion of their premarital exams (which includes screening for syphilis) took part in the study by filling in a form and being tested for viral hepatitis. The recruitment was carried out in Buenos Aires, Greater Cordoba, Rio Cuarto, Greater Mendoza, Greater Santa Fe and Rosario between September 2013 and October 2014.

Results: A total of 3,835 persons participated in the study out of which 1,922 (50.6%) were women and 1,993 were men (49.4%). The estimated syphilis prevalence was 0.74% (95% CI: 0.47-1.01), finding statistically significant difference between the area where the marriages were going to take place and the educational level (lower educational level, higher prevalence). The estimated prevalence for hepatitis A was 63.9% (95% CI: 62.4-65.5) with differences regarding age (the older, the higher the prevalence), province of birth, educational level (lower educational level, higher prevalence), housing type (most prevalent in people with deficient housing) and health insurance (more prevalent in people with no health insurance).

Conclusions: For hepatitis B, the estimated prevalence found for HBsAg was 0.26% (95% CI: 0.10-0.42) and 2% (95% CI:1.56-2.44) for anti-HBc. Finally, the estimated prevalence of hepatitis C was 0.26% (95% CI: 0.10-0.43). The only statistically significant difference found was in the number of deaths wrongly coded as “Acute Hepatitis type C” (8, 9). At the same time, as the ICD-10 indicates, “...Except in cases of disease by HIV, no infectious or parasitic disease may be accepted as causing a malignant tumour,” if a certificate states both HC and HV, the former must be selected as the underlying cause.

Conclusions: The rules of the current ICD-10 explain the large number of deaths wrongly coded as “Acute Hepatitis type C” and the invisibility of VH as the underlying cause of HC. This implies a real obstacle to the adequate description of the impact of viral hepatitis on public health.

http://dx.doi.org/10.7448/IAS.19.2.21078

VIROLOGY AND IMMUNOLOGY

P050
Integrated analysis of emergent drug resistance through 96 and 144 weeks from clinical studies of HIV-1 treatment-naive subjects receiving dolutegravir-based regimens
Michael Aboud1; Jim Demarest2; Romina Quercia3; Andrew Zolopa2; Marty St Clair4; Brian Wynne5; Mark Underwood2 and Catherine Granier1
1ViiV Healthcare, Brentford, UK. 2ViiV Healthcare, Research Triangle Park, USA. 3ViiV Healthcare, Upper Providence, PA, USA. 4GlaxoSmithKline, Stockley Park, UK.

Introduction: The integrase inhibitor dolutegravir (DTG) plus 2 NRTIs has been evaluated in three Phase 3 studies in treatment-naïve subjects. Dolutegravir-based regimens (DBRs) achieved non-inferiority in SPRING-2 versus RAL-based regimens, while superiority was achieved in SINGLE and FLAMINGO versus Atripla (ATR) and boosted darunavir (DRV/r)-based regimens, respectively.

Methodology: Genotypic and phenotypic resistance was analyzed on paired plasma from baseline and protocol-defined virologic failure (PDVF), regardless of plasma viral load (pVL) at PDVF. The frequency of reportable results with respect to pVL at PDVF was assessed.

Results: In total, 1,067 patients received a DBR. Table 1 summarizes pVL at PDVF and by reportable results. The range of pVL at PDVF was...
Abstracts of the HIV & Hepatitis in the Americas 2016 - Congress
Journal of the International AIDS Society 2016, 19 (Suppl 1)  
Poster Abstracts

Abstract P050–Table 1. Summary of pVL at PDVF and by reportable results according to class.

| Study          | Arm | N  | Log c/mL pVL Median (Range) | n (IN : PR/RT) | Log c/mL pVL Median (Range) | n (IN : PR/RT) | Resistance Detected¹ |
|----------------|-----|----|-----------------------------|----------------|-----------------------------|----------------|---------------------|
| SINGLE Wk 144  | DTG | 414| 2.14 (1.72–5.61)            | 19:26          | IN: 3.13 (1.72–5.61)/      | 0 : 0          | na                  |
|                | ATR | 419| 2.07 (1.70–4.91)            | 11:16          | PR/RT: 2.59 (1.82–5.61)    | 0 : 7          | 3.84 (2.12–4.61)    |
| SPRING-2 Wk 96 | DTG | 411| 1.94 (1.71–4.09)            | 10:14          | IN: 2.20 (1.76–4.09)/      | 0 : 0          | na                  |
|                | RAL | 411| 1.93 (1.70–4.95)            | 20:20          | PR/RT: 2.36 (1.73–4.09)    | 1 : 4          | 4.95 (1.72–4.95)    |
| FLAMINGO Wk 96 | DTG | 242| 3.17 (2.82, 3.36)           | 2:2            | IN: 3.17 (2.82–3.36)/      | 0 : 0          | na                  |
|                | DRV/r | 242| 3.62 (2.34–4.79)           | 4:4            | PR/RT: 3.62 (2.34–4.79)    | 0 : 0          | na                  |

¹IN: Integrase, PR/RT: protease/reverse transcriptase; #na = not applicable.

similar between arms and generally decreased at the confirmatory visit. No DTG or NRTI resistance has been selected in the DBRs. Only a few subjects in the ATR (n = 7, SINGLE) and RAL (n = 4, SPRING-2) arms had detectable resistance at PDVF. A minority of subjects across studies had pVL ≥500 c/mL at PDVF and using this cut-off for resistance analysis would have detected resistance in 6/7 ATR and 1/4 RAL PDVF.

Conclusions: DBRs demonstrated durable virologic suppression across three trials in treatment-naive patients through 96 and 144 weeks of treatment. Plasma viral load at time of PDVF was comparable between arms, and reportable resistance results were obtained across a range of pVL, including pVL <500 c/mL at PDVF. No resistance to DTG or NRTIs has been detected to date in clinical trials of treatment-naive patients receiving DBRs. Use in clinical practice will further inform the virologic characteristics of failure on a DBR.

http://dx.doi.org/10.7448/IAS.19.2.21079
# AUTHOR INDEX

| A                  |                       |
|--------------------|-----------------------|
| Aboud, M           | P039*, P050*          |
| Adaszko, A         | P022*, P032, P048, P049 |
| Adaszko, D         | P048                  |
| Ain, D             | P045                  |
| Alave, J           | P007                  |
| Alborna, CD        | P035                  |
| Almond, S          | P039                  |
| Andrade Villanueva, J | P004*, P007         |
| Angeleri, P        | P048*, P049*          |
| Arauz, AB          | O224                  |
| Arbelaez, F        | P006                  |
| Arribas, J         | P003                  |
| Arteta, Z          | P035                  |
| Atwood, S          | P030                  |
| Ayloot, A          | P039                  |
| Ayma, A            | P021                  |
| B                  |                       |
| Badial Hernandez, F | P018, P033           |
| Bank, L            | O225                  |
| Bastos Cabral, G   | P015                  |
| Bautista-Amoroco, H | P047*                |
| Beceril-Vargas, E  | P031, P041            |
| Bekker, L-G        | P020                  |
| Belauzaranz, F     | P038                  |
| Belauzaranz Amudio, P | O222*, P005*, P025   |
| Belloso, W         | P007                  |
| Beltran, C         | P037*                 |
| Bennett, S         | P020                  |
| Benzak, A          | P040                  |
| Bernal, F          | P042, P044            |
| Bird, M            | P021                  |
| Bonhomme, J        | O313, O314            |
| Bouchet, D         | P048                  |
| Brainard, D        | P008, P009, P045      |
| Bravo Garcia, E    | P036*                 |
| Brezzo, C          | P022, P032            |
| Brinson, C         | P003, P004            |
| Brunetta, J        | P003                  |
| Buggisch, P        | P045                  |
| Bull, M            | P016                  |
| C                  |                       |
| Cabrera Lopez, T de J | P033*               |
| Cabrera, A         | P035                  |
| Cabrera, S         | P035                  |
| Callebut, C        | P010                  |
| Camilo Campos, N   | P015                  |
| Campos, AF         | P046                  |
| Capuani, L         | P046                  |
| Caro-Vega, Y       | P005, P034            |
| Carrasco-Hernandez, R | P005               |
| Caserta, B         | P035                  |
| Casillas Rodriguez, J | P018, P028*         |
| Cassetti, I        | O224*                 |
| Castellanos-Dominguez, Y-Z | P047     |
| Castillo, A        | P024                  |
| Celi, AP            | P038                  |
| Cendejas, L        | P021                  |
| Cerqueira, N       | O223                  |
| Chacón-de-Mendieta, L | P047               |
| Chahin, C          | P037                  |
| Chanqueo, L        | P042*, P044*          |
| Cheinquier, N      | P008, P009, P045      |
| Chéret, A          | P003                  |
| Chokephaibi, K     | P020                  |
| Cid Vasque, H      | P018                  |
| Clarke, A          | P003, P004, P010      |
| Cloret, B          | P010                  |
| Clunck, N          | P003                  |
| Conde-Glez, CJ     | P019                  |
| Cooper, C          | P008, P009            |
| Coronel, E         | P048                  |
| Crabtree-Ramirez, B | P034                  |
| Cruz, JB           | P001*, P002, P025, P029, P033 |
| Cuello, H          | P048                  |
| Curry, M           | P045                  |
| D                  |                       |
| Daar, E            | P004                  |
| Das, M             | P003, P010            |
| Davis, A           | P006                  |
| de Kort, J         | O225                  |
| de Macedo Brígido, LF | P015                 |
| de Matos, MLM      | P046                  |
| De Oliveira, T     | O225                  |
| De Paz, M          | P007                  |
| de Souza Cavalcanti, J | P015                  |
| Demarest, J        | P015, O313*, O314     |
| Deschamps, MM      | P016                  |
| Devieux, J         | P030                  |
| Diaz, S            | P017*, P033            |
| Diego-Diaz, S      | P005                  |
| Dieterich, D       | P009                  |
| Domingo, R         | P024                  |
| Domingues, CSB     | P011*, P012*, P023*, P027* |
| Dorvil, N          | P030                  |
| Durán, A           | P022, P032*           |
| Duran, IA          | P024                  |
| E                  |                       |
| Eggleton, E        | P045                  |
| F                  |                       |
| Falistocco, C      | P032, P048, P049      |
| Farfán-Garcia, A-E | P047                  |
| Feld, J            | KL11*, P045*          |
| Fernández, M       | P002                  |
| Ferreya, VD        | P001, P002, P029      |
| Fonseca Pacheco, AG | P023                |
| Fordyce, M         | P003, P004, P010      |
| Fourie, J          | P020                  |
| Frantchev, Z       | P035*                 |
| Freitas, M         | P040                  |
| Fridborg, S        | P004                  |
| G                  |                       |
| Galarraga, O       | P019                  |
| Gallo, C           | P037                  |
| Ganley, KY         | P019*                 |
| Garcia-Vega, M     | P021                  |
| Gaur, A            | P020                  |
| Georges Kallés, E  | O223                  |
| German, P          | P008, P009            |
| Ghidinelli, M      | O231*                 |
| Giadalah, C        | P042                  |
| Gianna, MC         | P012, P023, P027      |
| Gladstone, D       | P013                  |
| Gonzalez Rodriguez, A | P018, P025, P028, P029, P033 |
| Gonzalez, A        | P001, P002, P017      |
| Granier, C         | P010                  |
| Gras Allain, N     | P018                  |
| Greco, M           | P038*                 |
| Guevel, C          | P022, P049            |
| Guitaue, C         | P030                  |
| Gulick, R          | KL33*                 |
| Guo, S             | P004                  |
| Gutierrez, E       | P042, P044            |
| H                  |                       |
| Hakim, A           | P016                  |
| Hennessey, K       | P030                  |
| Hernandez, H       | P049                  |
| Hirata, AH         | P001, P002*, P029     |
| Hofstra, LM        | O225                  |
| Hunt, P            | O221*                 |
| I                  |                       |
| Ingiliz, P         | P045                  |
| Iracheta, P        | P017                  |
| Irizarry-Gonzalez, L | P006                |
| Ivalo, S           | P013, P016*           |
| J                  |                       |
| Jannat-Khah, D     | O313, O314            |
| Jimenez Munguia, LM | P018                  |
| Jovet-Toledo, GG   | P006                  |
| Juarez, L          | P017                  |
| Julma, P           | O313, O314, P030      |
| K                  |                       |
| Kaynar, V          | P032                  |
| Kelly, K           | O225                  |
| Kizito, H          | P020                  |
| Kleinstein, SE     | P008, P009            |
| Koenig, E          | P010*, P020*          |
| Koenig, S          | P030                  |
| Kolling, A         | P040                  |
| Kowdley, K         | P008, P045            |
| Kretter, B         | P045                  |
About the journal
The Journal of the International AIDS Society, an official journal of the Society, provides a peer-reviewed, open access forum for essential and innovative HIV research, across all disciplines.

All articles published by the Journal of the International AIDS Society are freely accessible online. The editorial decisions are made independently by the journal’s editors-in-chief.

Email: editorial@jiasociety.org
Website: http://www.jiasociety.org
eISSN: 1758-2652

Editors
Editors-in-Chief:
Susan Kippax (Australia)
Papa Salif Sow (Senegal)
Mark Wainberg (Canada)

Deputy Editors:
Martin Holt (Australia)
Kayvon Modjarrad (United States)
Luis Soto-Ramirez (Mexico)
Iryna Zablotska (Australia)

Managing Editor:
Marlène Bras (Switzerland)

Editorial Assistant:
Helen Etya’ale (Switzerland)

Editorial Board:
Quarraisha Abdool Karim (South Africa)
Laith J Abu-Raddad (Qatar)
Dennis Altman (Australia)
Joseph Amon (United States)
Jintanat Ananworanich (Thailand)
Judith Auerbach (United States)
Francoise Barré-Sinoussi (France)
Chris Beyrer (United States)
Andrew Boule (South Africa)
Carlos Cáceres (Peru)
Elizabeth Connick (United States)
Mark Cotton (South Africa)
Jocelyn Dejong (Lebanon)
Diana Dickinson (Botswana)
Sergi Dvoriak (Ukraine)
Nathan Ford (South Africa)
Omar Galárraga (Mexico)
Diane Havlir (United States)
Akichi Iwamoto (Japan)
Adeeba Kamarulzaman (Malaysia)
Rami Kantor (United States)
Elly Katabira (Uganda)
Sukhontha Kongsin (Thailand)
Kathleen MacQueen (United States)
Navid Madani (United States)
Jacques Mokhbat (Lebanon)
Julio Montaner (Canada)
Nelly Mugo (Kenya)
Paula Mundhen (Uganda)
Christy Newman (Australia)
Héctor Pérez (Argentina)
Sai Subhasree Raghavan (India)
Renata Reis (Brazil)
Linda Richter (South Africa)
Jürgen Rockstroh (Germany)
Naomi Rutenberg (United States)
Gabriella Scarlatti (Italy)
Tim Spelman (Australia)
Ndèye Coumba Touné-Kane (Senegal)
Ian Weller (United Kingdom)
Alan Whiteside (South Africa)
David Wilson (Australia)
Iryna Zablotska (Australia)

Publisher
International AIDS Society
Avenue de France 23
1202 Geneva, Switzerland
Tel: +41 (0) 22 710 0800
Email: info@iasociety.org
Website: http://www.iasociety.org

Indexing/abstracting
The Journal of the International AIDS Society is indexed in a variety of databases including PubMed, PubMed Central, MEDLINE, Science Citation Index Expanded and Google Scholar. The journal’s impact factor is 5.090 (*2014 Journal Citation Reports®Science Edition - a Thomson Reuters product).

Advertising, sponsorship and donations
Please contact the editorial office if you are interested in advertising on our journal’s website. We also gladly receive inquiries on sponsorship and donations to support open access publications from authors in low- and middle-income countries.

Supplements
The Journal of the International AIDS Society publishes supplements, special issues and thematic series on own initiative or based on proposals by external organizations or authors. Inquiries can be sent to the editorial office at editorial@jiasociety.org. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print.

Disclaimer
The authors of the articles in this supplement carry the responsibility for the content and opinions expressed therein. The editors have made every effort to ensure that no inaccurate or misleading content or statements appear in this supplement. However, in all cases, the publisher, the editors and editorial board, and employees involved accept no liability for the consequences of any inaccurate or misleading content or statement.

Copyright
The content in this supplement is published under the Creative Commons Attribution 3.0 Unported Licence (http://creativecommons.org/licenses/by/3.0/). The license allows third parties to share the published work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear. Authors retain the copyright of their articles, with first publication rights granted to the Journal of the International AIDS Society.
